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—

The rate of absorption of poorly soluble drugs is dissolution
rate-limited. Slow dissolution results in incomplete, erratic
and unpredictable absorption. Two methods of increasing the dis
solution of two categories of drugs were investigated.
1.

The effect of two medicinally used surfactants, poloxalene and
dioctylsodium sulfosuccinate, on the dissolution of the sulfona
mides, sulfisoxazole and sulfadiazine was studied. A dramatic
increase in the dissolution rate of both the drugs was noted in
the presence of all concentrations of the surfactants. A signi
ficant but less dramatic increase in the absorption of these
drugs was brought about by the surfactants.

2.

Solid dispersions, 1 and 10% w/w of the cardiac glycosides
digitoxin and digoxin in two inert carriers, poloxalene and
deoxycholic acid, were prepared. All the solid dispersions
dissolved significantly faster than the pure drugs.
In all
cases, the 1% solid dispersions dissolved at a faster rate than
the 10% solid dispersions. As an indication of bioavailability,
the toxicity of the different preparations in mice was evaluated.
The 10% digitoxin solid dispersions in both the carriers showed
a significantly higher toxicity than the drug alone indicating
an increase in the bioavailability of the solid-dispersed drug.
The nature of solid dispersions obtained was studied by the
x-ray diffraction technique.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

TABLE OF CONTENTS

Page
ABSTRACT

..........................................................

LIST OF T A B L E S ....................................................

ü
V

LIST OF F I G U R E S ......................................................vii
PART ONE.

SULFONAMIDES

Chapter
I. I N T R O D U C T I O N .................................................

2

LITERATURE SURVEY ............................................

4

Mechanisms of Surfactant Effects on Drug Absorption . . . .
Effect of Surfactants on Solubility and Dissolution
Rate of D r u g s ............................................

4
S

OBJECTIVES OF R E S E A R C H ........ .. ...........................11
II.

III.

E X P E R I M E N T A L ........................................

12

M a t e r i a l s .................... ....................... ..
P r o c e d u r e s ................................................

12
12

RESULTS AND D I S C U S S I O N ......................................

18

Absorption Studies

........................................

PART TWO.

19

CARDIAC GLYCOSIDES

IV. I N T R O D U C T I O N ................................................... 46
SURVEY OF LITERATURE

........................................

48

SOLID DISPERSIONS.............................................. 50
Methods of Preparation of Solid Dispersions ..............
54
Classification of Solid Dispersions .......................
56
Methods of Determining Types of Solid Dispersions .........
61
Aging of Solid D i s p e r s i o n s .................................. 65
Review of In vivo S t u d i e s .................................... 66

111

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Chapter

V.

VI.

Page

OBJECTIVES OF R E S E A R C H ................

69

E X P E R I M E N T A L ..............................................

71

M a t e r i a l s ................................................
P r o c e d u r e s ..............................................

71
71

RESULTS AND D I S C U S S I O N ....................................

75

S U M M A R Y ....................................................

98

BIBLIOGRAPHY

....................................................

IV

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Ill

LIST OF TABLES

Table
I.

II.

III.

IV.

V.

VI.

VII.

VIII.

IX.

X.

XI.

XII.

XIII.

XIV.

Page
Absorption of Sulfisoxazole from Rat Intestinal Loops in
the Absence of any S urfactant...........................

24

Effect of 0.01% Poloxalene on the Absorption of
Sulfisoxazole from Rat Intestinal Loops .................

25

Effect of 0-1% Poloxalene on the Absorption of
Sulfisoxazole from Rat Intestinal Loops .................

26

Effect of 1.0% Poloxalene on the Absorption of
Sulfisoxazole from Rat Intestinal Loops ..................

27

Effect of 0.01% DOSSon the Absorption of Sulfisoxazole
from Rat Intestinal L o o p s ...............................

28

Effect of 0.1% DOSS on the Absorption of Sulfisoxazole
from Rat Intestinal L o o p s ...............................

29

Effect of 1.0% DOSS on the Absorption of Sulfisoxazole
from Rat Intestinal L o o p s ...............................

30

Absorption of Sulfadiazine from Rat Intestinal Loops
in the Absence of any S u r f a c t a n t ..........

32

Effect of 0,01% Poloxalene on the Absorption of
Sulfadiazine from Rat Intestinal Loops
.................

33

Effect of 0.1% Poloxalene on the Absorption of
Sulfadiazine from Rat Intestinal Loops .................

34

Effect of 0.01% DOSS on the Absorption of Sulfadiazine
from Rat Intestinal L o o p s ...............................

35

Effect of 0.1% DOSS on the Absorption of Sulfadiazine
from Rat Intestinal L o o p s ...............................

36

Effect of 0.01% Poloxalene on the 24-hr. Urinary
Excretion of Sulfisoxazole
.............................

39

Effect of 0.1% Poloxalene on the 24-hr. Urinary
Excretion of Sulfisoxazole .............................

40

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

T a b le
XV.

XVI.

XVII.

XVIII.

XIX.

XX.

XXI.

XXII.

XXIII.

XXIV.
XXV.

XXVI.

Page
Effect of 1.0% Poloxalene on the 24-hr. Urinary
Excretion of Sulfisoxazole .............................
Effect of 0.01% DOSS on the 24-hr. Urinary Excretion
of S u l f i s o x a z o l e .........................................

41

42

Effect of 0.1% DOSS on the 24-hr. Urinary Excretion
of S u l f i s o x a z o l e ...................................

43

Effect of 1.0% DOSS on the 24-hr. Urinary Excretion
of S u l f i s o x a z o l e .........................................

44

Dissolution Rate Studies of Digitoxin Test Preparations
in Water at 37“ ............................................

78

Oral Toxicity of Various Digitoxin Test Preparations
in M i c e ....................................................

81

Effect of Poloxalene and Deoxycholic Acid on
Solubility of Digitoxin inWater at 37“ ..................

86

Dissolution Rate Studies of Digoxin Test Preparations
in Water at 37“ .........................................

92

Effect of Poloxalene and Deoxycholic Acid on
Solubility of Digoxin inWater at37“ ....................

93

Oral Toxicity of Various DigoxinPreparations in Mice . . .

95

Effect of Aging on the Dissolution of Digitoxin
Test Preparations.........................................
Effect of Aging on the Dissolution of Digoxin
Test Preparations.....................................

VI

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

101

104

LIST OF FIGURES

Figures

Page

1.

Effect of Poloxalene on the Dissolution of Sulfadiazine

. .

20

2.

Effect of Poloxalene on the Dissolution of Sulfisoxazole . .

21

3.

Effect of Dioctyl Sodium Sulfosuccinate on the
Dissolution of Sulfadiazine ...............................

22

Effect of Dioctyl Sodium Sulfosuccinate on the
Dissolution of Sulfisoxazole ...............................

23

Phase Diagram of a Simple Eutectic Mixture with
Negligible Solid Solubility ...............................

56

Dissolution Rates of Digitoxin from Poloxalene Test
Preparations ................................................

77

Dissolution Rates of Digitoxin from Deoxycholic Acid
Test P r e p a r a t i o n s .........................................

85

Correlation Between the Amount of Digitoxin in Solution
at 60 min. and the Number of Mice Dead in 7 D a y s ..........

89

Dissolution Rates of Digoxin from Poloxalene Test
Preparations ................................................

91

Dissolution Rates of Digoxin from Deoxycholic Acid
Test P r e p a r a t i o n s ..........................................

97

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

Effect of Aging on the Dissolution Rates of Digitoxin
Coprecipitates .............................................

100

Effect of Aging on the Dissolution Rates of Digoxin
Coprecipitates .............................................

103

X-ray Diffraction Spectra of Treated and Untreated
D i g i t o x i n ..................................................

106

X-ray Diffraction Spectra of Treated and Untreated
Deoxycholic A c i d ...........................................

108

VIX

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ACKNOWLEDGEMENTS

The author wishes to sincerely thank Professor M. Wafik Gouda for
his guidance, directions, and above all, for his patience.

The author

also wishes to convey his sincere appreciation to Dr. Donald Canham for
his invaluable help throughout the study period.

viii

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

PART ONE

SULFONAMIDES
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CHAPTER I

INTRODUCTION

The biological availability of a drug is the result of many
processes.

Low solubility and slow dissolution are only two of many

factors which contribute to poor availability.

In order for an orally

administered solid drug to be absorbed, it must first dissolve in the
aqueous environment of the gastrointestinal tract.

An aqueous solubil

ity of less than 1% at 37® over a pH range of 1 to 7 suggests potential
problems in the absorption of a drug.

Noyes and Whitney (82) quantita

tively studied dissolution and derived the following equation:
dA

3#

=

k(C s-c)

CD

where A is the concentration at time t, and Cg is the equilibrium solu
bility of the solute at the experimental temperature.
In later studies surface area of the dissolving material was
incorporated to give:
dA

^

=

K S(Cg-C)

(2)

Brunner (16) used Pick's law of diffusion to establish a relationship
between the constant in the above equation and the diffusion coefficient
of the solute.
It is apparent from equation 2 that the dissolution kinetics are
subject to many influences.

From a pharmaceutical point of view, the
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3
factor which can be manipulated with the least difficulty to increase
dissolution rate is the surface area of the drug.

Sulfadiazine was one

of the first drugs whose absorption was shown to be dependent on par
ticle size.

Not only was the drug absorbed at a faster rate from the

smaller particles but also the total amount of the dose absorbed was
greater.

Takubo et al (111) found that the absorption of sulfanilamide

and sulfisoxazole from the rabbit rectum and intestine was influenced
by particle size.

The absorption rate constant was proportional to the

log of the reciprocal of the particle size and the dissolution rate
constant was proportional to the reciprocal of particle size.
' »
There are a number of other reported studies (33, 112) showing
that the absorption of sulfonamides is related to the dissolution rate
of drugs or their dosage forms.

The dissolution rate of a drug can be

increased by increasing its effective surface area, which is the area
in actual contact with the dissolution medium.

For hydrophobic materials

the effective surface area may be drastically smaller than the specific
area.

IVhen the particle size of a hydrophobic drug is reduced, the in

crease in effective surface area might not be anywhere close to the in
crease in its specific surface area.

This is because of the fact that

with an increase in surface area, there is a corresponding increase in
surface energy which causes the fine particles to adhere to each other
and form larger particles.
Effective surface area can also be increased without reducing
the particle size, by incorporating certain adjuvants in the dosage
form.

These adjuvants are called surface active agents, surfactants,

or association colloids.

They are compounds which, while soluble in a
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given liquid, tend to accumulate or be positively adsorbed at its inter
faces with air, another liquid, or a solid.

A single surfactant molecule

contains one or more hydrophobic portions and one or more hydrophilic
groups.

Depending on the hydrophilic moiety, these compounds are called,

anionic, cationic, or nonionic.
Surface active agents increase the dissolution rate of poorly
soluble drugs by decreasing the interfacial tension between the drug and
the dissolution medium, thus allowing the latter to wet the drug more
completely, or by means of micellar solubilization.

The latter mechanism

is prominent only in concentrations above the critical micelle concentra
tion CCMC).

Though a number of studies dealing with the effect of high

concentrations (above CMC) of surfactants on drug absorption have been
reported, their effect in low concentrations have not been widely studied.
Dioctylsodium sulfosuccinate (DOSS) and poloxalene are two sur
factants which are commonly used in medicine.

The effect of these two

surface active agents on absorption through various types of membranes
have been previously reported (45, 46, 55, 70).

This study was under

taken to determine the effect of DOSS and poloxalene on the dissolution
and absorption of the two sulfonamides, sulfisoxazole and sulfadiazine.
The data generated could help in determining which of the two surfactants
would be a better choice for incorporation in a suspension dosage form.

LITERATURE SURVEY

Mechanisms of Surfactant Effects on Drug Absorption

Surface active agents are used internally or externally in almost
every dosage form, including liquids, semisolids, and solids.
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They are

5
included in pharmaceutical preparations to act as wetting agents, dis
persing agents, foaming agents, emulsifying agents, etc.

There are

reports indicating that surface active agents increase as well as de
crease the absorption of drugs,
reports.

Blanpin (14) reviewed many of these

As Levy (60) has pointed out, much of the difficulty in anal

yzing these studies is because of the different types of effects these
agents exert.

They may exert their effect on the biological membrane

and modify its permeability to drugs, they may interact with the drug
or the dosage form or with the organism itself, exerting pharmacological
effects of their own.

This in turn might affect drug absorption.

To

complicate matters further, these effects might be operative at the same
time, some of which may affect drug absorption in the positive manner
and others in a negative manner.

The net effect in such a case will

depend on the relative magnitude of each.

Effect of Surfactants on Solubility and Dissolution Rate of Drugs

Those drugs whose absorption is dissolution rate-limited are the
ones which can be influenced most by surface active agents.

Two impor

tant parameters determining the dissolution rate of a drug are its
solubility in the dissolution medium and the surface area of the drug
exposed to the dissolution medium.

When the particle size is greater

than about 10 y, the rate of dissolution is directly proportional to the
surface area.

In this case, surface area, and not particle size per se,

is a factor controlling dissolution rate.

The initial rate of dissolu

tion, i.e., the rate at very low percentage saturations of the dissolu
tion medium, is directly proportional to the solubility of the drug in
the dissolution medium.
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When the surface area of a drug is increased by particle size
reduction, there is also a considerable increase in the surface free
energy.

The hydrophobic properties of the fine particles are increased

because of adsorption of air.

The relative magnitude of the interpar

ticulate binding force, such as electrostatic charge is also increased,
which leads to clunking.

These clumps, called aggregates or agglomer

ates, are..much larger in size than the individual particles.

The dis

solution rate is thus decreased instead of being increased due to
micronization (67).

The presence of a surface active agent in the dis

solving medium prevents the fine particles from forming aggregates by
improving the wetting of the particles.

Because of wetting, the fluid

surrounds the individual particles, displacing the air around them, and
a fast dissolution rate results.

The dissolution rate of aspirin powder

was found to be inversely proportional to the crystal size, but the
opposite was found true in tablets (27).

This was reported to be due to

the agglomeration of fine particles and it could be hindered by appro
priate adjuvants.
In a dissolution study (115), cylindrical compressed tablets
containing large pores were used to follow the dissolution process.
When distilled water was used as the dissolution medium, the surface
area of the pores was incompletely exposed to the solvent due to occlu
sion by air.

When the surface tension of the dissolution medium was

decreased, an increase in the dissolution rate was noted, because of
better wetting of the surface.

Similar effects were noted when the air

was evacuated from the pores.
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Premicellar concentrations of polyoxyethylene lauryl ether and
lysoleclthin (113) were found to enhance the dissolution rate of sali
cylic acid powder.

The same surfactants also increased the dissolution

rate of aspirin from a tablet dosage form but had no effect on the dis
solution rate of the drug from a capsule.

A good correlation was ob

tained between the surface tension of the polyoxyethylene lauryl ether
Solutions and the dissolution rates of aspirin from the tablets.

Short

et al (98) investigated the effect of low concentrations of an n-alkyl
polyoxyethylene surfactant on the dissolution of hydrocortisone.

It was

shown that the plot of the dissolution rate constant versus the surfac
tant concentration exhibited a maxima in the region of the CMC.

Finholt

and Solvang (34) studied the dissolution of phenacetin powder in 0.1
N hydrochloric acid containing various concentrations of polysobate 80.
Increasing the surfactant concentration from 0 to 0.01% caused a signi
ficant increase in the dissolution rate.

Beyond 0.01% and up to 0.2%,

little change in dissolution rate was observed.

The surface tension of

the dissolution medium was shown to have an appreciable effect on the
dissolution kinetics of the drug.
’Solubilization' is the term used to describe the manner in
which surface active agents increase the solubility of a material in a
given solvent.

McBain (76) described solubilized systems as those in

which the solubility of materials otherwise insoluble, or only poorly
soluble, in a given media, is increased due to the prior presence of
particles of colloidal dimensions, called micelles.
Wurster and Seitz (115) showed an increased solubility of ben
zoic acid at 0.2% concentration of sodium lauryl sulfate.
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shown by other workers (30, 49, 80) solubilization of some materials may
be brought about in concentrations of surfactants well below their CMC.
Micellar solutions of the bile salts, sodium cholate and sodium
deoxycholate enhanced the dissolution rate of griseofulvin and hexestrol.
The enhancement in the dissolution rates of these two drugs in the pre
sence of the bile salts was most probably due to a lowering of the inter
facial tension between the drug and the dissolution medium as well as
micellar solubilization.

The authors (9) suspected that since the con

centrations of the bile salts used was about four times their CMC values,
solubilization might have played a greater role.

Physiological concen

trations of lysolecithin (10) produced marked increases in the solubil
ity and dissolution rate of hexestrol, dienestrol, and griseofulvin.
Parrot and Sharma (84) studied the dissolution of benzoic acid
from constant surface tablets in aqueous solutions of four surfactants-tyloxapol, polysorbate 80, sodium lauryl sulfate, and poloxalkol (polox
alene).

A linear relationship between solubilization of benzoic acid

and concentration of the surface active agents was found to exist.

At

concentrations of these surface active agents less than the CMC, the
dissolution rate was only slightly increased due to improved wetting of
the drug surface.

At concentrations exceeding the CMC, the dissolution

rate was increased to a maximal rate by an increase in concentration of
tyloxapol, sodium lauryl sulfate and polysorbate 80.
trations, the dissolution rate decreased.
zoic acid was retarded by poloxalkol.

At higher concen

The dissolution rate of ben

Elworthy and Libscomp (31)

studied the dissolution of griseofulvin in water and in aqueous solutions
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of four nonionic surfactants.

They found that the surfactants increased

the dissolution rate of the drug.
Kellner et al (54) found that feeding cholesterol to rabbits
along with polysorbate 80 yielded blood levels of cholesterol two to
three times as high as those obtained when feeding cholesterol alone.
The authors suggested better émulsification of the drug in the presence
of the surfactant as the reason for increased absorption but it might
well have been due to increased solubility and dissolution rate of the
water-insoluble cholesterol brought about by polysorbate 80.

Fuchs and

Ingelfinger (35) found that sodium lauryl sulfate hastened the appearance and increased the levels of vitamin A in the blood of human subjects.
Krause (56) found that sodium lauryl sulfate incorporated into the pills
of G-strophanthin increased the absorption of the drug in dogs, guinea
pigs, rabbits, and cats.

The observed effect in both these studies was

postulated to be due to the increased solubility and higher rate of dis
solution of the drug in the presence of the surfactant.

The gastroin

testinal absorption of spironolactone was markedly improved when the drug
was administered with polysorbate 80.

It might have been due to the

solubilization and wetting effect of the surfactant (36).
Kakemi et al (52) found that the one hour blood level of sulfi
soxazole, after rectal administration of the drug as suspension contain
ing varying amounts of surfactant, increased with increasing concentra
tions of the surfactant up to a maximum of 20%.

This concentration of

the surfactant completely solubilized the excess drug.

It was found

that an eighteen fold increase in drug solubility in the presence of
20% surfactant resulted in a threefold increase in the initial blood
level.
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Bean and Berry (11) reviewed the work on antimicrobial activity
of solubilized products.

The same authors studied the antimicrobial

activity of benzyl chlorophenol and chloroxylenol in aqueous potassium
laurate solutions of constant surfactant/phenol ratio (12, 13).

Below

the CMC, the activity increased due to a reduction in surface tension
and an increase in phenol concentration.

Above the CMC, the activity

decreased because the phenol is now distributed between the aqueous
phase and the micellar pseudophase.

It is now known that the degree of

saturation of the aqueous phase rather than the concentration in the mi
cellar pseudophase determines the activity of a drug.

Solubilization of

salicylic acid (66), normally a well absorbed substance, decreased the
activity of the drug due to decreased absorption.

The effect of surfac

tants seems therefore to be related to the aqueous solubility of the
drug, and, as a consequence, its distribution between the aqueous and
micellar phases.
The time for which a drug remains in the stomach and the rate at
which it traverses the gastro intestinal tract are important determin
ants of the overall rate and extent of drug absorption.

Some of the

mechanisms by which surfactants can alter gastrointestinal motility and
gastric emptying have been studied by many workers (64, 83, 69, 93, 32,
51, 74).
Surface active agents are capable of exerting a direct action on
membranes, thereby modifying their permeability characteristics.
authors have studied this aspect:

(3, 65, 61, 6, 40, 114).

Various

Depending

on the nature and extent of drug-surfactant interaction the absorption
of drugs may be altered by surfactants.
findings:

Many authors have reported such

(90, 91, 92, 66, 52, 116).
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OBJECTIVES OF RESEARCH

The absorption of some sulfonamides from suspensions has been
shown to depend on particle size.

For example, sulfadiazine, when given

as a microcrystalline suspension was absorbed more rapidly and to a
greater extent than from a preparation of larger particles, with a sur
face area about 1/7 of the microcrystalline drug.

Moreover, the absorp

tion was more uniform, i.e., there was less variation between subjects,
with the fine particle suspension (88).

Similar results were obtained

by Boyd and Dingwall (15), who studied the absorption of sulfadiazine
from tablets made of conventional size material, a micronized drug sus
pension and a suspension of microcrystalline drug somewhat smaller in
size than the micronized particles.

This effect of particle size is due

largely to the increased dissolution rate in the gastrointestinal tract.
Since the dissolution of a drug can also be increased by increasing the
effective surface area and since surface active agents are known to
cause this, the present study was undertaken with the following in mind:
1.

To determine the effect of two medicinal surfactants, poloxalene
and dioctylsodium sulfosuccinate, on the dissolution of sulfadiazine
and sulfisoxazole, and,

2.

To determine the effect of these surfactants on the absorption of
the above drugs from rat gastrointestinal tract.
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CHAPTER II

EXPERIMENTAL

Materials

Sulfadiazine, U.S.P., Matheson, Coleman and Bell,
Sulfisoxazole, U.S.P., Hoffman LaRoche, New Jersey.
Dioctyl Sodium Sulfosuccinate, (DOSS), Aerosol OT 100%, Sargent Welch
Scientific Company, Illinois.
Poloxalene, 'Pluronic F 68 ’, Wyandotte Chemicals, Michigan.

Procedures

Intestinal Loop Technique.

Male Sprague Dawley rats (supplied by Horton

Labs., California) weighing between 200 and 300 gm were starved for
16-18 hours before the experiment, with water allowed ad libitum.

The

rats were anesthetized with ether and a midline incision was made to
expose the abdominal cavity.
5 ml normal saline.

The peritoneal cavity was hydrated with

The ileocecal end of the intestine was ligated and

a loose ligature placed about 2 cm proximal to the first.
sion was made between the two ligatures.

A small inci

About 2 cm distal to the

pyloric end of the intestine a small incision was made and a hypodermic
needle with a blunt end was inserted in the opening and secured tightly
with a silk suture.

Fifty milliliter normal saline, warmed to 37°, was

injected through a hypodermic needle, very slowly, to clear the intestine
12
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of particulate matter and the washings collected at the opening near the
ileocecal end.

Ten minutes after the washing, the ligature at the

ileocecal end was tightened.

The drug was administered through the

hypodermic needle as a suspension in 3.5 ml of water containing varying
concentrations of either of the surfactants.

The needle was immediately

pulled out, tightening the ligature simultaneously so that the drug sus
pension did not flow out.
and the anesthetic removed.

The abdominal cavity was closed with sutures
Three hours after the administration of

sulfadiazine or a half hour after sulfisoxazole, the animals were sac
rificed with ether and the whole intestinal loop excised.

Analysis of Drug in the Intestinal Loop.

The intestinal loop was placed

in a blender and homogenized with 10 ml of 0.1 N sodium hydroxide for
2 minutes.

The blender was then washed with water and the washings com

bined and volume made up to 100 ml.

An aliquot of the homogenate was

centrifuged at 5000 r.p.m. for 10 minutes.

Ten milliliter of the super

natant liquid was added to 10 ml of 35% w/v trichloroacetic acid, mixed
by inversion, and recentrifuged.

The supernate was filtered and 10 ml

of the filtrate was transferred to a 100 ml volumetric flask.

To the

flask was added, in succession, at 6 minute intervals, 10 ml each of
0.1% sodium nitrite (freshly prepared), 0.5% ammonium sulfamate and
0.1% N-l-naphthyl ethylene diamine dihydrochloride (NEDD) in 0.125 N HCl.
The flask was swirled after addition of each reagent to ensure proper
mixing.

The volume was made up with water and the absorbance read at

530 nm for sulfadiazine and at 533 nm for sulfisoxazole.
final solution was always between 1.3 and 1.4.

The pH of the

It was reported by Dux
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and Rosenblum (29) that in the final pH range of 1.0 to 1.6, the solu
tion exhibited greatest optical density and minimum pH sensitivity.

In

all analyses, a Beckman ACTA G U I spectrophotometer was used.

Drug Recovery.

To see if there was any effect of the surfactants on

drug recovery, the following study was performed:

After exposing the

intestine and making a loop, the animal was sacrificed in an ether tank
and the drug suspension in water or surfactant solution was injected.
After a period of time (half hour for sulfisoxazole and three hours for
sulfadiazine) the loop was excised and analyzed for drug content.

A

mean recovery of 100% was obtained in the presence and absence of the
surfactants.

Urinary Excretion Studies.

Male Sprague Dawley rats weighing between

200 and 300 gm were starved 16-18 hours prior to the experiment, water
allowed ad libitum.

The experiments were performed in a cross over

fashion such that each animal served as its own control.

Six animals

were used for each concentration of the two surfactants.

In each group

of six animals, three received the drug with surfactant first and the
other three received plain drug first.
was allowed before the crossover.
pension by gastric intubation.

A recovery period of three days

The drug was administered as a sus

The animals were then returned to indi

vidual metabolic cages and their urine collected for the next 24 hours.
During this period, solid food was withheld.

Analysis for Sulfisoxazole in the Urine.

The total (free as well as

acetylated) sulfisoxazole excreted in the urine in 24 hours was deter
mined

by the modified Bratton and Marshall method (29).

The urine was
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diluted to 100 ml with water and 10 ml of it transferred to a 100 ml
volumetric flask to which 10 ml of 0.5 N hydrochloric acid was added.
The mixture was heated in a steam bath for one hour.
5 ml of 0.5 N hydrochloric acid was added.

After cooling,

Then 10 ml each of the fol

lowing reagents, in succession at 6 minute intervals, was added:

0.1%

sodium nitrite, 0.5% ammonium sulfamate and 0.1% NEDD (in 0.125 N HCl).
The volume was made up with water and an

aliquot

filtered through a

Millipore and its absorbance determined against a blank at 533 nm.
final pH was always between 1.3 and 1.4.

The

It was found that the acid

present in the dye solution and an additional 5 ml of 0.5 N HCl added
before initiating the coupling gave a final pH in the desired range of
1.3 to 1.4.

Preparation of Drug Suspension.

The dosing volume for both the intes

tinal loop studies and the intact rat studies was held constant at 3.5
ml.

Eleven milligrams of drug was weighed in a dry syringe and the 3.5

ml fluid was used in portions to administer as much of the drug as pos
sible.

After administering the drug, the syringe was washed with 0.2

Molar, pH 7.5 phosphate buffer for sulfisoxazole or with 0.1 N hydro
chloric acid in the case of sulfadiazine and the washings suitably
diluted.

The absorbance was read at 252 nm for sulfisoxazole and at

240 nm for sulfadiazine and the amount of drug remaining in the syringe
calculated from a Beer’s Law plot.

The exact amount of drug adminis

tered to each animal was thus determined by subtracting the amount left
in the syringe from that originally weighed.

Solubility Studies.

Excess of drug (100 mg) was placed in Erlenmeyer

flasks together with 25 ml of 0.5 Molar, pH 6 phosphate buffer containing
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varying concentrations of either of the surfactants.

The flasks were

tightly stoppered and equilibrated in a Metabolyte water bath shaker main
tained at 37*.
sampling.

Equilibrium solubility was determined by repetitive

The amount of drug dissolved was determined spectrophotomet-

rically.

Dissolution Studies.

Dissolution rates were determined by the beaker

method of Levy (63) with slight modifications.
A 80/100 mesh powder was used.

The dissolution medium consisted

of 500 ml of 0.5 Molar, pH 6 phosphate buffer containing varying concen
trations of the surfactants.

A one-liter beaker was kept in a constant

temperature water bath (37 ± 0.1*) and a 3-blade, 1-3/4 inch diameter
polyethylene stirrer (No. 6160, Nalge Company) centered and its height
adjusted so that when the dissolution medium was added it would dip
3.5 cm in the liquid.

Sulfisoxazole (5 gm) or sulfadiazine (2 gm) was

added to the beaker and the fluid, warmed to 37*, was poured along the
walls of the beaker.

Before the addition of the fluid, the stirrer was

set to rotate at a speed of 60 r.p.m. by means of a variable speed over
head motor.

At frequent time intervals 2 ml of the dissolution medium

was pipeted out and filtered through a Millipore filter (0.45 v pore
size) into a flask kept at 37* to prevent possible crystallization of
the drug.

Two milliliters of fresh dissolution medium was immediately

added to the beaker to maintain the volume constant.

The amount of drug

in solution at various time intervals was determined spectrophotometrically at 252 nm in a pH 7.5 phosphate buffer for sulfisoxazole and at
240 nm in 0.1 N hydrochloric acid for sulfadiazine.

All dissolution

rate experiments were performed at least in duplicate.

A cumulative
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correction was made for the previously removed samples in determining
the total amount dissolved at a particular time by using the formula:
^

" ^'n'meas.
meas.

(Cs,meas.)

500
s+1

where Cn,meas. denotes the spectrophotometrically measured concentration,
and Cjj is the concentration of the n^h sampling expected in the medium
if the previous samples had not been removed.
The amount of surfactants present did not interfere with the
assay for the drug.
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CHAPTER III

RESULTS AND DISCUSSION

Effect of DOSS and Poloxalene on the Dissolution and Solubility of Sulfisoxazole and Sulfadiazine.

Figures 1 and 2 illustrate the effect of

poloxalene on the dissolution behavior of sulfadiazine and sulfisoxazole
respectively.

The presence of the surfactant in the dissolution medium

in all concentrations studied, caused a significant increase in the dis
solution rate of both the drugs.

In the case of sulfadiazine (Fig. 1),

as the concentration of poloxalene is increased from 0.001 to 0.1%,
there is a distinct increase in the dissolution rate.

In the case of

sulfisoxazole (Fig. 2), an increase in the surfactant concentration from
0.001 to 0.1% resulted in an initial increase in the dissolution of the
drug.

However, after about 3 minutes, sulfisoxazole dissolved to a

greater extent in 0.01% than in 0.1% solution of the surfactant.

This

slight decrease in dissolution at the higher surfactant concentration
could be the result of particle aggregation.
The dissolution behavior of sulfadiazine in the presence of DOSS
is shown in Figure 3.

DOSS in all concentrations studied significantly

enhanced the dissolution of the drug.

Increasing the concentration of

the surfactant from 0.001 to 0.1% had almost no effect on the drug's
dissolution.

18
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Figure 4 shows the dissolution behavior of sulfisoxazole in the
presence of various concentrations of DOSS.

As the surfactant concen

tration was increased, there was also an increase in the dissolution of
the drug.

The increased dissolution was not limited only to the initial

stages of the experiment, but was seen throughout the 30 minute period.
The solubility of sulfadiazine in pH 6 phosphate buffer is
13 mg/100 ml.

In the presence of 0.001, 0.01 and 0.1% of either of the

surfactants, the solubility was increased only slightly, to 13.5 mg/100
ml.

The solubility of sulfisoxazole in plain buffer and in the presence

of all concentrations of the two surfactants is 242.4 mg/100 ml.

Sur

face active agents generally increase the solubility of a drug only
when they are present in concentrations above their CMC.
Since micellar solubilization is ruled out by the results ob
tained in the solubility studies, the enhanced dissolution of the two
sulfonamides in the presence of the surfactants must be due to better
wetting of the drug particles by the dissolution fluid.

Surface active

agents are known to reduce the interfacial tension between the drug and
the dissolution medium.

This lowering of interfacial tension increases

the effective surface area of the drug (34, 67, 62) which results in
faster dissolution.

Absorption Studies

Effect of DOSS and Poloxalene on the Absorption of Sulfadiazine and
Sulfisoxazole from Rat Intestinal Loops.

The absorption of sulfisoxa

zole from rat intestinal loops and the effect of poloxalene and DOSS on
this process are presented in Tables I through VII.

The presence of
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TABLE I

Absorption of Sulfisoxazole from
Rat Intestinal Loops in the
Absence of any Surfactant

Percentage
Absorbed

Rat No.

mg Administered

1

10.4

4.7

45.0

2

9.2

4.3

46.6

3

9.9

5.0

50.7

4

8.8

3.0

34.2

5

8.0

3.4

42.7

6

9.3

4.9

52. 3

mg Absorbed

Mean - 45.25
Standard Deviation - 6.5
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TABLE II

Effect of 0.01% Poloxalene on the Absorption of
Sulfisoxazole from Rat Intestinal Loops

Percentage
Absorbed

Rat No.

mg Administered

mg Absorbed

1

10.2

6.4

62.5

2

10.1

5.6

55.4

3

10.4

5.6

54.1

4

10.2

5.6

54.3

5

10.2

5.2

51.5

6

10.3

6.0

58.8

Mean - 56 .1
Standard Deviation - 3.9
t* + 3.5 (Significantly different from control at p <.01)

*2-sampIe t test
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TABLE III

Effect of 0.1% Poloxalene on the Absorption of
Sulfisoxazole from Rat Intestinal Loops

Percentage
Absorbed

Rat No.

mg Administered

mg Absorbed

1

10.8

4.7

43.4

2

10.6

4.9

46.3

3

10.2

6.7

65.7

4

10.2

6.8

66.5

5

9.8

5.7

57.9

6

9.9

6. 3

63.8

Mean - 57.27
Standard Deviation - 10.1
t* = 2.4496 (Significantly different from control at p <.05)

*2-sample t test
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TABLE IV

Effect of 1.0% Poloxalene on the Absorption of
Sulfisoxazole from Rat Intestinal Loops

Rat No.

mg Administered

mg Absorbed

Percentage
Absorbed

1

10.4

5.8

56.0

2

10.3

5.1

50.0

3

10.4

7.3

69.8

4

10.4

7.4

71.1

5

10.4

5.3

51.3

6

10.2

5.6

54.5

Mean - 58.78
Standard Deviation - 9.3
t* = 2.9250 (Significantly different from control at p <.02)

^2-sample t test
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TABLE V

Effect of 0.01% DOSS on the Absorption of
Sulfisoxazole from Rat Intestinal Loops

Percentage
Absorbed

Rat No.

mg Administered

1

9.8

5.1

52.3

2

8.2

4.9

59.6

3

9.2

6.4

70.1

4

9.8

4.8

48.6

5

10.1

4.5

44.9

6

10.0

4.8

48.0

mg Absorbed

Mean - 53.92
Standard Deviation - 9.4
t* = 1.8600 (Significantly different from control at p <.10)

*2~sample t test

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

29

TABLE VI

Effect of 0.1% DOSS on the Absorption of
Sulfisoxazole from Rat Intestinal Loops

Percentage
Absorbed

Rat No.

mg Administered

1

10.9

7.2

65.9

2

10.7

6.9

64.3

3

10.7

5.9

54.5

4

10.8

4.9

45.2

5

10.9

5.5

50.4

6

10.9

5.4

49.7

mg Absorbed

Mean - 55.0
Standard Deviation - 8.4
t* = 2.2552 (Significantly different from control at p <.05)

*2-sample t test
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TABLE VII

Effect of 1.0% DOSS on the Absorption of
Sulfisoxazole from Rat Intestinal Loops

mg Absorbed

Percentage
Absorbed

Rat No.

mg Administered

1

10.4

4.4

42.5

2

10.5

4.6

43.9

3

10.5

4.7

44.6

4

10.5

5.6

53,5

5

10.5

4.8

46.0

6

10.4

6.4

60.9

Mean - 48.57
Standard Deviation - 7.2
t* = 0.8404 (Not significant compared to control)

'2-sample t test
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0.01% poloxalene resulted in a 24% increase in drug absorption over that
of the control.

Further increase in poloxalene concentration did not

result in any further significant increase in the absorption of sulfis
oxazole.

The presence of 0.01 and 0.1% DOSS resulted in a 19-20% in

crease in drug absorption.

When the drug was administered in 1% DOSS,

the increase was only 7%.
The absorption of sulfadiazine and the effect of poloxalene and
DOSS is presented in Tables VIII through XII.

The presence of 0.01 and

0.1% poloxalene resulted in a 22% increase in the absorption of sulfad
iazine.

The increase in sulfadiazine absorption was 16.5% and 24% for

0.01 and 0.1% DOSS respectively.
As discussed in an earlier section, surface active agents can
improve drug absorption by increasing the solubility and dissolution
rate of the drug in the gastrointestinal fluids, or by exerting a direct
action on the membrane and thus enhancing the membrane permeability, or
by altering gastric emptying, or by forming a more absorbable complex
with the drug.

The solubility data rule out complex formation and

solubilizing effects of the surfactants used.

The in situ intestinal

loop preparation is not subject to gastric emptying effects.

The in

creased drug absorption therefore must be due to enhanced dissolution
or membrane effects.

In previous studies, poloxalene has been shown

not to have a membrane effect.

Therefore, the increased absorption of

sulfisoxazole and sulfadiazine in the presence of all concentrations of
this surfactant must be due to improved dissolution of the two drugs in
the intestinal loop.

The difference in the increase in drug absorption

caused by different concentrations of poloxalene is not significant at
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TABLE VIII

Absorption of Sulfadiazine from Rat Intestinal
Loops in the Absence of any Surfactants

Percentage
Absorbed

Rat No.

mg Administered

mg Absorbed

1

10.1

5.9

58.9

2

10.0

5.6

55.8

3

10.0

5.1

51.0

4

10.0

5. 8

58.0

5

10.2

5.6

55.1

6

9.7

6.4

66.0

Mean - 57.47
Standard Deviation - 5.0
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TABLE IX

.Effect of 0.01% Poloxalene on the Absorption of
Sulfadiazine from Rat Intestinal Loops

Percentage
Absorbed

Rat No.

mg Administered

mg Absorbed

1

10.7

7.3

68.2

2

10.6

8.3

77.6

3

10.4

7.1

68.3

4

9.8

6.5

67.0

5

9.4

7.1

75.3

6

10.2

7.3

70.8

Mean - 70.65
Standard Deviation - 3.67
t* = 5.0906 (Significantly different from control at p <.001)

*2-saraple t test
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TABLE X

Effect of 0.1% Poloxalene on the Absorption
of Sulfadiazine from Rat Intestinal Loops

Percentage
Absorbed

Rat No.

mg Administered

mg Absorbed

1

10.8

7.9

73.0

2

10.6

7.8

73.3

3

10.7

7.0

65.6

4

10.6

7.4

69.6

5

10.6

7.1

67.1

6

10.3

7.4

72.0

Mean - 70.10
Standard Deviation - 3.22
t* = 5.1993 (Significantly different from control at p <.001)

^2-sample t test
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TABLE XI

Effect of 0.01% DOSS on the Absorption of
Sulfadiazine from Rat Intestinal Loops

Rat No.

mg Administered

mg Absorbed

Percentage
Absorbed

1

10,1

7.2

71.0

2

10.0

6.0

59. 7

3

10.0

6.9

68.5

4

8.7

6.6

76.0

5

9.8

5.9

59.5

Mean - 66.94
Standard Deviation - 7.2
t* = 2.5676 (Significantly different from control at p <.05)

*2-sample t test
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TABLE XII

Effect of 0.1% DOSS on the Absorption of
Sulfadiazine from Rat Intestinal Loops

Percentage
Absorbed

Rat No.

mg Administered

mg Absorbed

I

11.0

7.9

71.7

2

11.0

7.9

72.5

3

11.0

7.3

66.6

4

10.9

7.4

67.9

5

10.9

8.5

78.1

6

11.0

7.7

70.7

Mean - 71.25
Standard Deviation - 4.1
t* = 5.2448 (Significantly different from control at p <.001)

*2-sample t test
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at any reasonable probability levels.

It is therefore suspected that a

minimum concentration of poloxalene which is enough to cause better wet
ting of the drug particles will do an equally good job of improving drug
absorption as any higher concentration will do.
In the case of DOSS, drug absorption might be affected by two
mechanisms.

One, the dissolution effect due to improved wetting of the

drug; and, two, a membrane effect.
shown to have a membrane effect.

This surface active agent has been
In the presence of low concentration

(below CMC) of DOSS, both mechanisms, better wetting and increased mem
brane permeability, aid in. improving drug absorption.

But at higher

concentrations, though both of these mechanisms are still in operation,
a third factor comes into play.

The drug is entrapped in surfactant

micelles and since micelie-entrapped drug is not available for absorp
tion, the rate of absorption of the drug is reduced.

This is what is

suspected to have happened to account for the reduced absorption of
sulfisoxazole in the presence of 1% DOSS.
The extent of increase in the absorption of both sulfisoxazole
and sulfadiazine does not correlate quantitatively with the increase in
their in vitro dissolution rates caused by the presence of either of
the surfactants.

The in situ intestinal loop preparation utilized in

this study does not rule out the presence of residual mucin and bile.
Both of these physiological materials are known to be highly surface
active.

Their presence in the intestinal loop will tend to mask or

minimize the surface active properties of surfactants administered along
with the drug.

However, since these physiological materials are common

to all the animals used in the study, i.e., control as well as surfactant
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groups, the increase in drug absorption brought about in the presence
of DOSS and poloxalene is due to the effect of these agents.
Though a quantitative relationship between dissolution and ab
sorption is not evident, a qualitative one is nevertheless present.

A

significant increase in the dissolution (over the control) is observed
in the presence of 0.001% of the surfactants.

Increasing the concentra

tion further does not result in further significant increase in drug
dissolution.

In absorption studies too, the lowest concentration of the

surfactants causes a significant increase in drug absorption which is
not improved by higher concentrations.
The extent of improvement in the dissolution and absorption of
the drugs studied is the same for both poloxalene and DOSS.

The latter

has been shown in prior studies to have a direct effect on the perme
ability of membranes.

Based on these data, it is postulated that polox

alene is a better choice over DOSS for incorporation in the suspension
dosage form of poorly soluble drugs.

Absorption of Sulfisoxazole from Intact Rats.

The effect of various

concentrations of poloxalene and DOSS on the 24 hour urinary excretion
of sulfisoxazole is presented in Tables XIII and XVIII.

Neither of the

surfactants had any significant effect on the amount of drug absorbed
in 24 hours.

These results coupled with the intestinal loop studies

indicate that the surfactants studied increase the rate of drug absorp
tion but do not alter the total amount absorbed.

Studies in man also

indicated a difference in rate but not in the extent of urinary excre
tion of sulfisoxazole (73, 7).
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TABLE XIII

Effect of 0.01% Poloxalene on the 24-hr.
Urinary Excretion of Sulfisoxazole

Control
Rat
No.

Surfactant

mg
Administered

mg
Excreted

%
Absorbed

mg
Administered

mg
Excreted

%
Absorbed

1

8.64

6.53

75-6

9.28

7.24

78.0

2

9.17

7.11

77.5

9.09

7.6

83.6

3

9.09

6.8

74.8

9.61

8.68

90 3

4

8.44

6.12

72.5

9.37

7.09

75.7

5

9.19

6.95

75.6

9.59

7.44

77.6

6

9.17

7.69

83.9

9.31

6.94

74.5

Mean - 76.65

Mean - 79.95

Standard Deviation - 3.9

Standard Deviation - 6.0
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TABLE XIV

Effect of 0.1% Poloxalene on the 24-hr.
Urinary Excretion of Sulfisoxazole

Control
Rat
No.

Surfactant

mg
Administered

mg
Excreted

%
Absorbed

mg
Administered

mg
Excreted

%
Absorbed

1

9.49

7.36

77.6

9.92

7.44

75.0

2

8.93

6.78

75.9

9.87

8.43

85.4

3

8.74

6.13

70.1

9.87

8.60

87.1

4

9.41

7.36

78.2

9.59

7.44

77.6

5

9.71

7.93

81.7

9.79

8.10

82.7

6

9.57

8.26

86.3

9.75

7.02

72.0

Mean - 78. 3

Mean - 79. 97

Standard Deviation - 5.5

Standard Deviation - 6.0
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TABLE XV

Effect of 1.0% Poloxalene on the 24-hr.
Urinary Excretion of Sulfisoxazole

Control
Rat
No.

Surfactant

mg
Administered

mg
Excreted

%
Absorbed

mg
Administered

mg
Excreted

%
Absorbed

1

9.25

6.61

71.5

9.94

8.26

83.1

2

9.46

8.6

90.9

9.96

8.1

81.3

3

9.73

8.6

88.4

9.96

8.6

86. 3

4

9.78

6.65

68.0

9.96

8.6

86.3

5

8.86

6.12

69.1

9.94

8.43

84.8

6

10.14

7.19

70.9

9.37

7.44

79.4

Mean - 76. 47

Mean - 83. 53

Standard Deviation - 10.3

Standard Deviation - 2.8
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TABLE XVI

Effect of 0.01% DOSS on the 24-hr.
Urinary Excretion of Sulfisoxazole

Control
Rat
No.

Surfactant

mg
Administered

mg
Excreted

%
Absorbed

mg
Administered

mg
Excreted

%
Absorbed

I

8.74

6.12

70.0

9.69

7,85

81.0

2

8.45

5.36

63.4

9.53

7.89

82.8

3

9.05

6.61

73.0

9.46

7.98

84.4

4

8.78

6.32

72.0

8.99

6.26

69.6

5

8.92

7.83

87.8

9.25

6.61

71.5

6

9.0

7.34

81.6

9.06

5.27

58.2

Mean - 74. 63

Mean - 74. 58

Standard Deviation - 8.7

Standard Deviation - 10.1

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

43

TABLE XVII

Effect of 0.1% DOSS on the 24-hr.
Urinary Excretion of Sulfisoxazole

Control
Rat
No.

mg
Administered

mg
Excreted

1

8.94

6.28

2

9.29

3

Surfactant
%
Absorbed

%
Absorbed

mg
Administered

mg
Excreted

70.20

9.90

8.25

83.30

7.04

75.80

9.96

8.51

85.40

9.32

6.45

69.20

9.98

8.68

87.00

4

9.57

6.90

72.10

9.96

9.90

99.40

5

9.04

7.59

84.00

9.95

7.60

76.40

6

9.20

7.52

81.7

9.94

6.82

68.6

Mean - 75 -5

Mean - 83. 35

Standard Deviation - 6.2

Standard Deviation - 10.4
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TABLE XVIII

Effect of 1.0% DOSS on the 24-hr.
Urinary Excretion of Sulfisoxazole

Control
Rat
No-

Surfactant

mg
Administered

mg
Excreted

%
Absorbed

mg
Administered

mg
Excreted

%
Absorbed

I

9.52

8.5

89.3

9.96

8.51

85.4

2

9.18

7.52

81.9

9.97

8.47

85.0

3

9.42

7.93

84.2

9.96

7.83

78.6

4

9.74

8.43

86.6

9.91

9.34

94,2

5

9.67

8.02

82.9

9.99

7.77

77.8

6

9.33

6.98

74.8

9.01

90.1

10.0

Mean - 83. 28

Mean - 85. 18

Standard Deviation - 4.9

Standard Deviation - 6.4
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PART TWO

CARDIAC GLYCOSIDES
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CHAPTER IV

INTRODUCTION

In the area of bioavailability, no other single drug probably
ever received as much attention as has digoxin.
et al,

In 1971, Lindenbaum

(68) reported marked differences in the serum levels of digoxin,

when four different tablet preparations of digoxin were administered
to healthy volunteers.

This difference in serum levels was observed

even from tablets from the same manufacturer.

Though this study did

not conclusively prove that the bioavailability of digoxin from various
tablets was different, only that the rates of absorption were different,
the study acted as a primer for more detailed work.

Since then, numer

ous reports have appeared, proving beyond any doubt, that the bioavail
ability of digoxin from its tablet dosage forms is quite variable.

In

many studies, a correlation between the digoxin tablet dissolution rate,
in vitro, and the total availability of the drug, in vivo, was found,
indicating that the absorption of digoxin is dissolution rate-limited.
Though digitoxin is also suspected to exhibit differences in bioavail
ability from its solid dosage forms, this drug has not been investigated
as thoroughly as digoxin.
The potential for variability in absorption increases greatly
with incompletely absorbed drugs.

For drugs like digitoxin and digoxin,

which have a steep dose-response curve and narrow range between toxic

46
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and therapeutic dose, it is imperative that their absorption be uniform
and not subject to great intersubject and intrasubject variations.
Available information at this time indicates that the differences in
bioavailability of digoxin and digitoxin from their solid oral dosage
forms are due to their poor solubility and hence low rates of dissolu
tion in the fluids of the gastrointestinal tract.

Poor formulation of

a dosage form magnifies these factors.
Since the absorption of these two cardiac glycosides is dissolu
tion rate limited and since they are absorbed passively from the stomach
and upper portions of the small intestine, it follows that if the drugs
are not in solution in the fluids of these regions, they will not be
absorbed into the systemic circulation.

Manninen et al (72) found that

propantheline increased serum levels of digoxin while metoclopramide
decreased the serum levels of digoxin administered as tablets.

Propan

theline had no effect on the absorption of a solution of digoxin given
orally.

Since propantheline reduces and metoclopramide increases gas

trointestinal motility, the authors concluded that the absorption of
digoxin from tablets is affected by the rate at which the dosage form
travels down the gastrointestinal tract.

Medin and Nyberg (77) studied

the dissolution characteristics of the tablets of digoxin used by
Manninen et al (72) and found that they had a very low rate of dissolu
tion.

They concluded that slow dissolution from these tablets is a

necessary condition for the observations reported by Manninen et al (72)
If the tablets were rapidly dissolving ones, GI motility might have had
no effect as was observed for the digoxin solution.
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It was the purpose of the present study to try and improve the
dissolution of digitoxin and digoxin in order to assure more uniform
absorption.

One of the means of increasing dissolution rates is to

reduce the drug particle size.

SURVEY OF LITERATURE

When a drug is administered orally in solid form as a tablet,
capsule or suspension, its absorption is frequently found to be depen
dent on how fast it goes into solution in the fluids of the GI tract.
Absorption in this case is said to be dissolution-rate limited and any
factor that influences the dissolution rate will influence the absorp
tion.

As pointed out by Gibaldi (38), if a drug is more rapidly and/or

more completely absorbed from solution than from a solid form, its
absorption is quite likely dissolution rate limited.
Noyes and Whitney (82) were the first to describe dissolution
quantitatively:
dA/dt = KS (Cg-C)

(1)

where dA/dt is the amount of drug dissolved per unit time, K is the
intrinsic dissolution rate constant and is equal to D/h, where D is the
diffusion coefficient of the drug and h is the thickness of the diffu
sion layer, S is the surface area of the dissolving drug, Cg is the
concentration of the drug at the drug-solvent interface (which is essen
tially equal to the solubility of the drug in the solvent) and C is the
concentration of drug in the bulk of the solvent at time t .

In dissolu

tion rate limited absorption, C is negligible compared to Cg and there
fore equation 1 can be written as :
dA/dt = DSCg/h

(2)
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The diffusion coefficient D and the solubility Cs usually in
crease with temperature, thus making dissolution rate temperature de
pendent.

D is inversely proportional to the viscosity of the medium

and therefore an increase in viscosity leads to a decrease in the rate
of dissolution.

The thickness of the diffusion layer h, depends on the

agitation intensity of the solvent around the dissolving particle.

The

greater the agitation, the thinner the layer and greater the dissolution
rate.

Any factor that affects the solubility Cs, influences the disso

lution rate proportionately.
creasing the surface area.

In this study we were concerned with in
This can be brought about by decreasing

the particle size of the drug.

Particle size effects are particularly

important when dealing with slowly dissolving, poorly soluble materials.
A reduction of particle size results in more rapid dissolution and ab
sorption of a drug.

And in cases where dissolution rate is so low

that incomplete absorption occurs, a reduction in particle size results
in more complete absorption.

It should be pointed out that the equa

tions presented are for solids which maintain a constant surface through
out the dissolution process.

Slightly more involved equations are

needed to represent accurately the dissolution process of multiparticu
late systems and for particles whose surface area changes as the disso
lution proceeds.
There are many ways of achieving a reduction in particle size,
ranging from simple grinding in a mortar to the use of modern techniques
like ultrasonic waves

(97, 50, 102).

Perhaps the most commonly used

method of presenting fine particles to the gastrointestinal fluids is
the use of micronized or microcrystalline particles.

In addition to
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these methods, where particle size is reduced outside the biological
system, there are ways of obtaining very fine particles within the gas
trointestinal tract.

If a drug is administered as a solution in a

water-miscible organic solvent or if a water soluble salt of a weak acid
is administered as an aqueous solution, the subsequent dilution with the
acidic fluids of the stomach causes the drug to be precipitated in fine
form (59).
Water-soluble salts of many poorly soluble drugs have been used
as solid dosage forms.

However, there are some drawbacks to their usage.

It was shown that the soluble sodium salt of novobiocin had slower dis
solution rate and gave lower plasma levels of novobiocin compared to
the less soluble amorphous form of novobiocin (81).

This is because the

sodium salt had reacted with the atmospheric carbon dioxide and water to
precipitate out the poorly soluble parent compound.

Also, the alkalinity

of some salts may lead to gastric distress.

SOLID DISPERSIONS

The reduction of particle size does not always result in in
creased dissolution and absorption.

This is because of the aggregation

of the fine particles due to increased surface energy and the subsequent
stronger Vander Waal's forces of attraction.

Lin et al (67) showed that

micronized particles of griseofulvin and glutethimide had a slower dis
solution rate compared to coarser particles.

Photomicrographs taken

after 2 hours of dissolution showed that the particulate agglomerates
of the micronized samples were larger in size than the coarser particles.
The electrostatic charge of the powders was seen to increase with
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decrease in particle size.

Moreover, fine powders are not easily wetted

in water and wetting is the first step towards their dissolution (58).

Definition.

The terra "solid dispersion", as pointed out by Chiou and

Riegelman (26) refers to "the dispersion of one or more active ingred
ients in an inert carrier or matrix at solid state prepared by the melt
ing (fusion), solvent, or melting-solvent method".

When the solvent

method is used, the terra "coprecipitate" has also been used.

To achieve

fast release of a drug from a carrier it is generally necessary that the
latter be highly soluble (there are exceptions, viz., nitrofurantoindeoxycholic acid coprecipitate, reserpine deoxycholic acid coprecipitate)
and that the drug be a minor component on the molar basis.
Sekiguchi and Obi (94) in 1961, introduced a unique approach of
reducing particle size, that of solid dispersions.

It consists of dis

persing a poorly soluble drug by fusion or solvent methods in a highly
water soluble, pharmacologically inert carrier.

When this system comes

in contact with the GI fluids, the carrier immediately dissolves, re
leasing the drug in the form of very fine particles or even in molecular
form.

Because of the increased surface area of the drug, it dissolves

rapidly.

Levy (59) and Kanig (53) indicated the possibility of using a

solid solution approach in which the drug is molecularly dispersed in a
soluble carrier.
Sekiguchi et al (94) showed that solid dispersions of chloram
phenicol in urea, at a weight fraction of 20:100 had a faster rate of
dissolution and absorption.
size reduction.

They attributed this effect to particle

Goldberg et al (41, 44) after examining the phase dia

grams presented by Sekiguchi et al (94) purposed that the binary system
of chloramphenicol-urea should be classified as a partial solid solution
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and not as a simple eutectic mixture.

Chiou (18) reexamined the same

data and after further study proposed that the "original suggestion of
Sekiguchi et al (94) of a particle-size effect in increasing dissolution
and absorption of chloramphenicol is more in accord with the physicalchemical facts discussed here".

Goldberg et al (41, 42, 43, 44) in a

series of reports during 1965-1966 discussed the advantages of solid
solutions over the eutectic mixture.

Chiou and Riegelman (26) reviewed

the literature on solid dispersions.

Tachibana and Nakamura (110) used

the solvent method to prepare a coprecipitate of 3-carotene and watersoluble polymers like polyvinylpyrrolidone.

The dissolution rate of

griseofulvin was markedly enhanced by dispersing it in polyvinylpyrroli
done by the solvent method (75).

The mechanism of increased dissolution

rate of sulfathiazole dispersed in polyvinylpyrrolidone was discussed
by Simonelli et al (100).

Chiou and Riegelman (22) studied the disso

lution characteristics of griseofulvin dispersed in polyethylene glycol
of different molecular weights, in pentaerythritol, pentaerythrityl
tetra acetate, and citric acid by the fusion method.

Of these systems,

the citric acid glass solution has the fastest dissolution rate for
griseofulvin.

The same authors (23, 24) showed that griseofulvin dis

persed in polyethylene glycol 6000 was rapidly and almost completely
absorbed in dogs and man, whereas the commercial micronized griseofulvin
was only 30-60% absorbed.

Svoboda et al (109), in a preliminary study,

found polyvinylpyrrolidone coprecipitated acronycine to be more active
than acronycine itself towards two tumors.
Chiou and Riegelman (25) reported that solid dispersions of
digitoxin and some steroids in polyethylene glycol prepared by the
fusion technique had significantly higher rates of dissolution.
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and Bates (106) found that with a 1:5 reserpine-polyvinylpyrrolidone co
precipitate both the rate and extent of absorption of reserpine in the
rat were significantly higher than that following either pure reserpine
or a 1:5 reserpine:polyvinylpyrrolidone physical mixture.

The in vitro

dissolution characteristics of the three test preparations correlated
very well with the in vivo absorption data.

Dissolution rates of drugs

solid-dispersed in polyethylene glycol 4000 were studied by Reiss (89).
Drugs that were not soluble in polyethylene glycol 4000 did not show an
increased dissolution rate while those that were soluble showed an in
crease.

Stoll et al (105) studied the dissolution and absorption of

nitrofurantoin dispersed in deoxycholic acid by the solvent method.
They found that the dissolution rate of the dispersed system was six
times greater than the pure drug at pH 7.4.

At pH 1.2, the initial dis

solution rate of the coprecipitate was higher than that of the pure drug
but became slower after 35 minutes.

The rate and extent of unchanged

drug excreted in the urine was significantly greater when the copreci
pitate was given to humans than when the pure drug was administered.
Stupak and Bates (107) studied the dissolution and toxicity (in rats)
of digitoxin in pure form as well as a 1:9 (w/w) coprecipitate in poly
vinylpyrrolidone.

They reported that about 11 times as much pure drug

would have to be administered to reach the same amount of drug in the
body as that attained following the administration of the drug as a
coprecipitate.

A correlation between the in vitro dissolution rates and

in vivo toxicities of the test systems was found.
Partial solid solutions of corticosteroids in mannitol and glass
(so called because of appearance) dispersions in dextrose, galactose and
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sucrose were prepared by Allen (5).

The solid dispersions had a markedly

higher dissolution rate compared to plain corticosteroid powder.

The

dissolution and absorption rates of a eutectic mixture of phénobarbital
in urea were reported to be higher than those of pure phénobarbital (1).
Solid dispersions of primidone in citric acid ranging from 1-30%
w/w were made by the fusion process and examined by x-ray diffraction
and differential scanning calorimetry.

Glasses containing 1-3% w/w of

primidone could not be classified from the x-ray data but melting point
data suggested the drug could be molecularly dispersed.

Samples con

taining 5-15% of the drug were simple eutectic mixtures and in the 30%
glass, primidone was present in the amorphous form.

It was noted that

the primidone recrystallizing from the glass solution was a different
polymorphic form than the one used to prepare the solid dispersion (108).

Methods of Preparation of Solid Dispersions

Melting Method.

The melting or fusion method of preparing solid dis

persions was first proposed by Sekiguchi et al (94).

The physical

mixture of drug and carrier was heated until both components melted and
the melt was then cooled and solidified rapidly, under vigorous stir
ring in an ice bath.

Some modifications of this technique were to pour

the melt onto ferrite or steel plates and cooling by flowing air or
water on the other side of the plates.

Systems of griseofulvin-citric

acid were found to harden more rapidly at 37* C rather than at room
temperature (22).

The advantage of the direct melting method is its

simplicity and economy.

Also, because of the sudden quenching of the

melt, a finer dispersion of the drug in the matrix results.
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technique can, however, be applied only to those materials which are
stable at high temperatures.

Melting under vacuum or a blanket of nit

rogen to prevent oxidation has been employed (87).

Chiou found some de

composition of digitoxin when he employed the fusion method.

Since the

melting point of a binary system depends on its composition, some com
binations might have a melting point lower than those of either of their
ingredients.

In such cases the fusion techniques might be applicable

even though the conponents might decompose near their individual melting
point.

Solvent Method:

This method involves the dissolving of the two ingred

ients, drug and carrier, in a common solvent and evaporating the solvent
in vacuo.

The advantage of this method is that there is no chance of

decomposition of the drug.

The drawbacks are many— long time required

to evaporate the solvent, cost of the solvents, the difficulty in com
pletely removing the solvent and the possible adverse effect of the
traces of solvent on the chemical stability of the drug.

Also, a super-

saturation of the drug cannot be obtained except in highly viscous
systems.

Melting-Solvent Method.

A method which possesses the advantages of both

the solvent and the fusion methods is the melting-solvent method.

The

drug is dissolved in a minimal amount of solvent and the resulting solu
tion incorporated into the melt of a water soluble matrix or carrier.
However, this technique can be used only for drugs with a very low thera
peutic dose.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

56
Classification of Solid Dispersions

Chiou and Riegelman (26) classified solid dispersions into six
main groups:

(1) Simple eutectic mixtures,

glass solutions and glass suspensions,

(2) solid solutions, (3)

(4) amorphous precipitation,

(5)

compound or complex formations between drug and carrier, and, (6) any
combinations of (1) through (5).

Simple Eutectic Mixtures.

A simple eutectic mixture results when a melt

of two substances which, show negligible solid-solid solubility and com
plete liquid miscibility, is rapidly solidified.

From a thermodynamic

point of view such a system is regarded as an intimate physical mix of
its two crystalline components.
Based on the assumption that the two components are present in
very small crystals, when a eutectic mixture (composition E in Figure 1)
is exposed to the dissolution fluids, the carrier goes into solution
immediately, exposing the drug, which because of its large surface area
also dissolves rapidly (94).

In addition to the reduced crystal size,

the following factors might also be playing a role in the increased rate
of dissolution:

LIQUID SOLUTIOl

I— J

SOLID B
+ LIQUID

SOLID A + LIQUID

SOLID A /|ND SOLID B
A (100%)

E

B(100%)

Figure 5--Phase diagram of a simple eutectic mixture with
negligible solid solubility.
(From ref. 26).
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(a)

If most of the drug crystallites are extremely small its

solubility would be higher.
(b)

As the carrier dissolves, a saturated solution of it sur

rounds the drug particles, and a possible solubilizing effect on the
drug might be operative.

This was demonstrated by the faster dissolu

tion rate of acetaminophen from its physical mixture with urea.

The

fact that the solubility of acetaminophen in water was higher in thepre
sence of urea lends further support to the hypothesis of a solubilizing
effect in the microenvironment of the drug particles (44).

Bates (8)

also suggested a similar mechanism for the increased dissolution rate of
reserpine from a physical mixture with polyvinylpyrrolidone.
(c)

When very fine particles of a poorly soluble drug are put

in an aqueous media, the particles tend to form aggregates and agglom
erates.

This problem is not encountered with solid dispersions because

they are separated by the water soluble carrier.

As the carrier dis

solves, the drug particles become surrounded by the aqueous media which
results in better wetting.
(d)

An increased rate of dissolution and absorption would also

occur if the drug crystallizes in a metastable form from the fused mix
ture.

Since a metastable crystalline form has higher solubility, this

would result in an improved dissolution.

If the drug does in fact

crystallize in a metastable form, it is possible that after a length of
time, the dissolution rate of the eutectic would not be the same as
when it was freshly prepared.
The composition of the eutectic determines to some extent the
particle size of the crystallite.

If it is made up of a small weight

fraction of the drug, a finer crystallization can be obtained.
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Solid Solutions.

A solid solution, as the name implies, consists of a

solid solute dissolved in a solid solvent.

It was suggested (41) that

a solid solution of a poorly soluble drug in a rapidly soluble matrix
has a faster dissolution rate compared to a eutectic mixture because
the drug is present in its smallest state of subdivision, the molecular
state, in a solid solution.

In addition to this extremely fine particle

size obtained in a solid solution, the factors (a-c) discussed under
Simple Eutectic Mixtures might also be responsible for a high rate of
dissolution from a solid solution.

As pointed out by Chiou and Riegelman

(26), "the advantage of a solid solution may not be so significant if it
is exposed to a medium with a volume much less capable to dissolve all
the drug".

If this is done, the drug might precipitate unless it is

being absorbed or removed in some other way.
Based on the crystalline structure, solid solutions can be div
ided into substitutional or interstitial solid solutions.

In the sub

stitutional type, a molecule of the solute replaces a molecule of the
solvent in the crystal lattice of the solid solvent.

To achieve an ex

tensive solid solution of this type, the size of the solute and solvent
molecule should be very close to each other.
In interstitial

solid

solutions, a solute molecule resides in

the interstitial space of the solvent crystal lattice.

It is obvious

that the size of the solute is critical in achieving such a solid solu
tion.

Glass Solutions and Glass Suspensions.

"A glass solution is a homogen

eous, glassy system in which a solute dissolves in a glassy solvent."
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Glass suspension is a mixture in which precipitated particles are sus
pended in a glassy solvent.

The term glass is used here to mean the

transparency and brittleness of the material.

Since a glass solution is

closer in similarity to a liquid solution than a solid solution, its
lattice energy is expected to be much lower.

The dissolution rate of

drugs in glassy solutions was therefore expected to be much faster than
that in a solid solution.

It was also pointed out (26) that when the

solute content exceeds the solubility, the particle size of crystalli
zation of the solute is much smaller in a glass solution than in a
solid solution.

This was said to be due to the difficult crystal growth

in the viscous medium.

Griseofulvin showed a marked increase in disso

lution rate in a citric acid glass solution (22).

Amorphous Precipitations in a Crystalline Carrier.

In these systems the

drug is present in an amorphous form in a crystalline carrier.

Since

the amorphous form of a drug is its highest energy form, it should,
theoretically, dissolve much more rapidly than a crystalline form.

It

was suggested by Chiou and Niazi (20) that the increased oral absorp
tion of sulfathiazole from the sulfathiazole-urea systems (94) was
mainly due to the presence of the drug in an amorphous form.

Compound or Complex Formation.

Scheme 1 (26) represents the dissolution

and absorption of a drug from a complex or compound.
dissolution
Kj
Dn Cm ---------- *■ Dn Cm v -ÿ - (solid)
(solution)
^
I absorption

+ mC
(solution)
| absorption

blood stream or circulation
Where D = drug
C - soluble carrier
Scheme I
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It is seen that the availability of a drug depends on the solu
bility, the dissociation constant, and the intrinsic absorption rate of
the complex.

Though the water-soluble polymers may be suitable for use

as carriers in making solid dispersions of many drugs, the possibility
of complex formation must be given due attention.

The pharmacological

action of penicillin, novocaine, prostigmine, hexobarbital, quinine (85)
and hexylresorcinol (37) was retarded by polyvinylpyrrolidone.

The re

duced rates of dissolution and permeation of phénobarbital through
everted rat guts was shown to be due to complex formation between the
drug and polyethylene glycol 4000 or 6000 (101).

Though the fact that

the solubility of griseofulvin in 7% aqueous polyethylene glycol 6000
is doubled indicates complexation, such a water-soluble complex did not
retard the oral absorption of the drug in man and dogs (24, 23).

The

formation of a soluble complex with a low association constant can in
crease dissolution and absorption of a poorly soluble drug.

The forma

tion of complex in the melt state does not necessarily mean it will
occur in a liquid medium too; the reverse is also true.

Although suc

cinic acid increased the solubility of griseofulvin in water, their
interaction could not be detected in the phase diagrams (19).

Combinations and Miscellaneous Mechanisms.

Sometimes a combination of

any of the five groups discussed might contribute to the formation of a
solid dispersion and, therefore, the increased dissolution and absorp
tion of such a system is due to the combined influence of different
mechanisms.

Thus, if griseofulvin is dispersed in high concentrations

in polyethylene glycol, it may exist in both molecular state as well as
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microcrystalline particles.

The coprecipitates^of reserpine with various

bile acids such as deoxycholic acid (71), cholic, lithocholic, and tri
hydroxy cholane (28) had greater blepharoptotic activity in mice com
pared to the pure drug.

This effect was postulated to be due to factors

like decreased particle size, better wetting, reduced surface tension,
etc.

Methods of Determining Types of Solid Dispersions

A single method rarely provides complete information about the
physical nature of a solid dispersion and therefore a combination of two
or more methods is needed for its complete elucidation.

Thermal Analysis.

Several techniques based on the principle of change

of thermal energy with temperature, constitute the most common means of
studying the physicochemical interaction of two or more components.
(a) Cooling-curve Method:

Physical mixtures of various compositions

are heated until a homogeneous melt results and the temperature is then
recorded as a function of time.

From a series of such temperature-time

curves, a phase diagram is constructed.

A large amount of sample is

needed, and only those samples which are stable when melted can be used.
Moreover, it is time consuming; and, if cooling is rapid, slope changes
might be missed.

Small solid-solid solubility cannot be detected.

Guillory et al (47) used this method to construct phase diagrams of
deoxycholic acid-menadione and caffeine-phenobarbital.
(b) Thaw-melt Method:
just begins to melt.

Thaw point is the temperature at which a solid

A mixture of the components is prepared by the
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solvent method or the fusion method and then the thaw point is observed
by gradually heating it in a capillary tube.

A stirring device in the

capillary was used (96) to achieve more accurate results.

The stirring,

while achieving uniform systems, affects the melting point but not the
thaw point.

The thaw point can be used to differentiate between a simple

eutectic mixture from a limited solid solution.

Since this method de

pends on subjective observations, results are not quite reproducible.
The thaw point had a range of six degrees for a chloramphenicol-urea
system (95).
(c) Thermomicroscopie Method:

A physical mixture of the components

on a glass slide covered with a cover slip is heated until it melts
completely.

It is cooled and then heated at a slow, steady rate and the

thaw and melting points are observed using a hot-stage polarizing micro
scope.

The method is simple and needs small quantities of the sample

but can be used for thermally stable mixtures only and being subjective
may not give reproducible results.

Chiou and Niazi (21) using differential

thermal analysis and x-ray diffraction, disproved the existence of a
partial solid solution of griseofulvin in succinic acid, which was re
ported by Goldberg et al (43) who used the thermomicroscopic method to
reach their conclusions.
(d) Differential Thermal Analysis (DTA):

This is a highly repro

ducible method of constructing phase diagrams.

It consists of record

ing the differential effects caused by physical and chemical changes
when a material is heated at a steady rate.

Polymorphic transformations,

evaporation, sublimation, and other types of decomposition can be
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detected, in addition to thawing and melting points.

Small amounts of

eutectic can be very easily detected by this method.

X-Ray Diffraction Method.

It consists of measuring the intensity of

x-rays as a function of diffraction angles by the sample.

DTA and x-ray

diffraction methods, in combination, seem to give the most information
any two methods can give about the physicochemical interactions in a
solid dispersion system.

The combination has been put to extensive use

in studying sulfathiazole-urea (20), chloramphenicol-urea (18),
griseofulvin-succinic acid (21) systems.
A diffraction spectrum which shows the diffraction peaks of each
crystalline component, indicates a simple eutectic mixture.

The lattice

parameter of the solvent crystal, in a solid solution of the substitu
tional type, may be either increased, decreased or unchanged, depending
on the relative size of the solute atom or molecule (103).

In a contin

uous solid solution, there is a shift of the diffraction lines from the
position in one pure component to those in the other (17).

A gradual

shift in the positions with changes in composition quite often indicates
that a solid solution exists.
the lattice parameter.

This gradual shift is due to changes in

In a diffraction spectrum of a solid solution of

the interstitial type, the peaks due to the solvent, i.e., the carrier,
may or may not be changed, but those due to the solute will disappear.
The x-ray diffraction technique has also been employed to quanti
tate the concentration of a crystalline component in a mixture (17, 2,
57).

It is obvious that if the concentration of the crystalline compon

ent is extremely low, or if the diffraction intensity of this component
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is very weak, it is not possible to quantify its concentration.

A broad

ening and an increase in the height of the diffraction peaks might indi
cate crystallite size reduction, usually below 0.2 p.

Simonelli et al

(100) attributed the loss of sulfathiazole diffraction peaks to the ex
tremely fine crystalline dispersion of the drug in polyvinylpyrrolidone.
In addition to detecting simple eutectic mixtures and solid solu
tions, the x-ray method can also help in detecting compound or complex
formation.

The spectra of a complex are quite different from the spectra

of its components.

If the solute is present in an amorphous form or if

it exists as a molecular dispersion, the diffraction peaks of the solute
disappear.

In such a case, the x-ray diffraction spectra cannot be

utilized to differentiate one from the other unless there is a change in
the lattice parameter of the solvent.

This is encountered especially in

the cases where a drug is present in low concentrations in a solid dis
persion system.

Microscopic Method.

This has been used to study the morphology (95) and

polymorphism (48) of solid dispersed systems.

Spectroscopic Method.

B-carotene, dispersed in low concentration in

polyvinylpyrrolidone, was examined by the visible absorption spectro
scopic method (110).

The spectrum of the B-carotene dispersed in poly

vinylpyrrolidone resembled that of 3-carotene dissolved in organic sol
vents but not that of 3-carotene particles.

This indicates that 3-

carotene is molecularly dispersed in the carrier.

No marked interaction

between 3-carotene and the carrier was suspected because the I R bands
of the dispersed 3-carotene showed no detectable shift.
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Dissolution Rate Method.

Allen and Kwan (4) proposed this method to

evaluate the degree of crystallinity in solid-solid equilibria.

The

molecular dispersion (i.e., glass or solid solution) and a physical mix
ture of the same chemical composition are compressed into constantsurface tablets and the in vitro dissolution rates of the solute compon
ent are compared.

Though the simplicity of the method makes it attrac

tive, it can be applied only to those systems where a constant surface
can be maintained throughout the period of study.

To apply this method,

it is mandatory that (1) the dissolution rate be proportional to the
surface area of the tablet,

(2) the difference between the dissolution

rates of the physical mixture and the dispersed system be large, and
(3) the drug present in both the systems be the same polymorphic form.
In addition, the assumption that the particle size of the drug released
from the solid or glass solution does not affect the dissolution rate
is made.

This assumption is still to be proved.

Aging of Solid Dispersions

Either because of coarsening of dispersed phase particles or
because of change of a metastable form to a more stable form, both of
which are possible due to aging, the increased dissolution and absorp
tion of a freshly prepared solid dispersion may not be seen after a
length of time.

The drug literature does not contain many reports

dealing with this topic.

Different polymorphic forms in the solid dis

persion might have different chemical stabilities (48).

Chiou and Niazi

(20) found that the DTA thermograms and the x-ray diffraction spectra
of solid dispersions of sulfathiazole in urea showed changes after aging.
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They noticed that the diffraction spectrum of freshly prepared 52% sul
fathiazole solid dispersion had no peaks due to sulfathiazole but the
same sample after being kept at 27° for 2 weeks showed some diffraction
peaks of sulfathiazole Form II.

It was found that this appearance of

Form II was temperature dependent.

Review of In Vivo Studies

Sulfathiazole-Urea Systems.

Sekiguchi and Obi (94) showed that the ab

sorption of sulfathiazole was both faster and higher when the drug was
administered as an eutectic mixture than the 50-100 mesh particles of
the pure drug.

In comparing the physical mixture of sulfathiazole and

urea with plain sulfathiazole, no differences in the drug absorption
were noted.

The solubility of the drug in the presence of urea was seen

to be decreased.

On the basis of these results the authors concluded

that urea does not enhance the absorption of sulfathiazole due to any
physiological or physicochemical factors and that the increased absorp
tion of the drug from a eutectic mixture is because of the presence of
the drug in a microcrystalline state.

Chloramphenicol-Urea Systems.

In studies with rabbits (95), a suspen

sion of a 20% chloramphenicol-80% urea solid dispersion produced a
higher and faster absorption in the first hour than the pure chloram
phenicol.

The total area under the blood level-time curves was the same

for both dosage forms.

When capsules were administered, the solid dis

persion gave a more dramatic increase in drug absorption over the first
four-hour period.

The solid dispersion of 76% chloramphenicol-24% urea,

the eutectic composition, given in both capsule and suspension form, had
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lower absorption than the pure drug.

As was pointed out earlier, when

a solute is present in lower concentrations, a finer particle-size dis
persion is obtained.

This might have been the reason for the difference

in absorption between solid dispersions of the two compositions studied.

Reserpine-Bile Acid Coprecipitates.

The blepharoptotic activity of re-

serpine when administered as a coprecipitate with deoxycholic acid to
mice was significantly enhanced and the onset of action was also con
siderably reduced (71).

This enhancement was generally increased as

the concentration of the drug in the coprecipitate decreased, with the
exception of the 1:32 molar ratio of reserpine to deoxycholic acid,
which was the lowest concentration dispersion studied.
tion with the in vitro dissolution rate was found (39).

A rank correla
Since deoxy

cholic acid is not a normal bile acid for mice, Decato et al (28) then
made coprecipitates of reserpine with cholic acid (indigenous to mice)
and other bile acids not present in mice (lithocholic acid, trihydroxycholane and cholanic acid) to study if the enhanced blepharoptotic
activity of the deoxycholic acid coprecipitate was limited to this acid
only.

It was found also that coprecipitates with cholic and lithocholic

acids had significantly increased blepharoptotic activity, trihydroxycholane system had only a slight increase in activity and cholanic acid
system about the same activity as the reserpine base.

Stoll et al (104)

in order to elucidate the mechanism of increased blepharoptotic activity
of these systems undertook the study of their surface tension and dis
solution properties.

A qualitative correlation between surface tension-

lowering ability and increased blepharoptotic activity was noted.
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rate of dissolution of reserpine from the coprecipitates in a 1:16 molar
ratio showed a rank order correlation with in vivo potency.

Griseofulvin-Polyethylene Glycol Systems.

A comparison of the avail

ability of griseofulvin from solid dispersed systems and micronized com
mercially available powders was carried out in dogs (23) and man (24).
Total urinary excretion data for 48 hours showed that 88% of dispersed
(10% w/w) griseofulvin, 45% micronized griseofulvin in capsule form and
33% of micronized griseofulvin in tablet form were absorbed.

A linear

relationship between the amount absorbed and logarithm of the in vitro
dissolution rates was found.

The absorption of griseofulvin administer

ed to man as 10 and 25% dispersions in polyethylene glycol 6000 was al
most complete and the absorption was over within about two hours.

Mic

ronized griseofulvin was only 43% absorbed and continued for 30-80 hours.

Nitrofurantoin-Deoxycholic Acid Coprecipitates.

The in vivo absorption

of a 1:5 coprecipitate, a 1:5 physical mixture and pure nitrofurantoin
was determined.

The coprecipitate showed significant increases in both

the initial urinary excretion rate and the cumulative excretion of nit
rofurantoin over the other two systems.

In pH 7.4 buffer, the dissolu

tion rate of the coprecipitate system was six times greater than that of
the physical mixture (105).

Digitoxin-Polyvinylpyrrolidone Coprecipitates.

Oral toxicity experiments

were carried out in rats to give an indication of the total availability
of digitoxin when the drug was administered as a 10% w/w digitoxinpolyvinylpyrrolidone coprecipitate.

The LDgQ of pure digitoxin was
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found to be 88 mg/kg, and the LDgg of the coprecipitate was 7.8 mg/kg.
The animals which received toxic doses of the coprecipitate died much
earlier than those receiving the pure drug (107).

OBJECTIVES OF RESEARCH

The rate of absorption of poorly-soluble drugs like digoxin and
digitoxin is dissolution rate-limited.

Slow dissolution results in in

complete, erratic and unpredictable absorption.

The inter-subject and

intra-subject variation in the absorption of orally administered solid
preparations of digoxin obtained from different manufacturers, and from
different lots of the same manufacturer has been well documented in
current literature.

This variation in absorption in normal, healthy

subjects has been repeatedly stressed to be due to the differences in
the dissolution rates of the solid oral dosage forms and not due to any
biological factors.

Solid dosage forms of digitoxin are also suspected

of exhibiting bioavailability differences.

Increasing the dissolution

rate of these drugs would perhaps minimize the variation in their oral
absoiption.
One way of increasing dissolution rates of drugs is to decrease
their particle size.
dispersions.
1.

A unique way of achieving this is through solid

The purpose of this study was:

To prepare coprecipitates of digoxin and digitoxin in two carriers,
poloxalene and deoxycholic acid and to determine their dissolution
characteristics in water,

2.

To assess the relative toxicity of the digitoxin and digoxin copre
cipitates in mice, as an indicator of oral absorption, and
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3.

To examine the nature of solid dispersions obtained by use of the
x-ray diffraction technique.
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CHAPTER V

EXPERIMENTAL

Materials

Digoxin, Lanoxin^, Lot No. 57177, Burroughs Wellcome Co,
Digitoxin, Lot No, W11097, Eli Lilly and Co.
Poloxalene, Pluronic F-68^, Wyandotte Chemicals.
Deoxycholic acid. Nutritional Biochemicals Corp.

Procedures

Preparation of Coprecipitates.
dispersions was employed.

The solvent method of preparing solid

The drug and carrier, in amounts which would

give 1 and 10% w/w of the drug in the coprecipitate system were dissolved
in alcohol.

The solvent was removed in a rotary evaporator, under vacuum

and the system left under vacuum overnight.

The next morning, the co

precipitate was ground in a mortar and sieved.

The fraction which passed

through a number 80 sieve but did not pass through a 100 mesh sieve was
collected and used for in vitro or in vivo studies.

Precipitated digi

toxin and digoxin were prepared by treating the drugs in a similar manner.
Physical mixtures composed of 1 and 10% w/w of the drugs and deoxycholic
acid were prepared by mixing the components on paper with a spatula.
In the case of poloxalene, which is flaky and does not permit
powdering to make a physical mixture with the drugs, its solution was

71
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employed.

This solution contained either 135 mg or 1485 mg of it in

500 ml water, which correspond to the amounts present in its 10 and 1%
coprecipitates respectively.

Determination of Dissolution Rates.

The dissolution characteristics of

Cl) digitoxin and digoxin in the form of 1 and 10% w/w coprecipitates
in the two carriers,

(2) pure digitoxin and digoxin,

digitoxin and digoxin, and,

(3) precipitated

(4) physical mixtures of the drugs with the

two carriers were determined.

In all cases, the amount used contained

15 mg of the drugs.
The beaker method of Levy (63) with slight modifications was
used.

The dissolution medium consisted of 500 ml of water maintained at

37*, in a one-liter beaker immersed in a constant temperature water bath.
Stirring was provided by a 3-blade, 1-3/4 inch diameter polyethylene
stirrer (No. 6160, Nalge) rotating at a speed of 60 rpm and dipped in
the water to a depth of 3.5 cm.
mesh powder was always used.

Unless otherwise specified, a 80/100

The test system was added to the dissolu

tion medium and 5 ml samples taken out every half hour for the next
three hours and filtered through a Millipore into a flask kept at 37°
to prevent crystallization of the drug.
tion medium was added back to

Five milliliter fresh dissolu

the beaker after each sampling.

The

amount of drug in solution was determined by the slightly modified color
imetric method of Mesnard and Devaux (79).
iment was run in duplicate.

Each dissolution rate exper

A cumulative correction was made for the

previously removed samples in determining the total amount dissolved at
a particular time by using the formula:
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n —1
-

Cn,meas.

5

- ^

•

5 Z Z

where Cn,meas. denotes the spectrophotometrically measured concentration,
and Cn is the concentration of the nth sampling expected in the medium
if the previous samples had not been removed.
The amount of carrier present did not interfere with the assay
for the drugs.

Solubility Determinations.

The solubility of digitoxin and digoxin in

water at 37® was determined.

Also, the effect of two concentrations of

poloxalene and deoxycholic acid, those corresponding to the 1 and 10%
coprecipitate systems, on the solubility of digitoxin and digoxin was
determined.
Excess of the drugs (20 mg) were placed in Erlenmeyer flasks
along with 20 ml of water or 20 ml of water and the carriers.

The flasks

were tightly stoppered and equilibrated at 37® in a Metabolyte water bath
shaker.

Equilibrium solubility was determined by repetitive sampling.

Assay Procedure.

The colorimetric assay of Mesnard and Devaux (79) was

used to analyse any and all solutions of digitoxin and digoxin.

The

presence of poloxalene or deoxycholic acid did not interfere with the
assay.
To 3 ml of drug solution was added 0.5 ml of 0.01 N periodic
acid in 0.1 N sulfuric acid.

After allowing a 10 minute oxidation per

iod, 1 ml of 2% sodium arsenite solution in 0.5 N hydrochloric acid was
added to stop the oxidation.

Four milliliter of the mixture was added

to 4 ml of a 0.6% aqueous solution of thiobarbituric acid adjusted to
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pH 2, in a 10 ml volumetric flask.

The flask was then heated in a boil

ing water bath for 20 minutes after which it was cooled to room temper
ature and the volume made up with distilled water.
read at 530 nm against a blank treated similarly.

The absorbance was
A Beer's Law plot was

constructed and was used for determining the drug concentrations in the
dissolution studies, solubility studies and in analyzing the coprecipi
tate systems for drug content.

Toxicity Studies in Mice.

The absorption of a drug may be indirectly

assessed by determining its oral toxicity.

To accomplish this, the

relative toxicities of pure digitoxin and digoxin were compared with
that of the 10% physical mixtures and coprecipitates of the two drugs
in the two carriers.

Protocol for in Vivo Studies.

Male albino mice (Horton Labs., California),

weighing 16-28 gm were deprived of food 16-18 hours prior to the drug ad
ministration.

Water was allowed ad libitum.

The drug was administered

by gastric intubation as a suspension in a 0.5% w/v methyl cellulose
(100 cp) aqueous vehicle.

The concentration of the suspension was ad

justed such that the dose to be administered would be contained in a
volume of 0.2 ml per 10 gm (for digitoxin) or 0.4 ml per 10 gm (for dig
oxin) body weight.

The animals were returned to cages after drug admin

istration and food and water allowed ad libitum.

The number of deaths in

seven days after administration was noted.
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CHAPTER VI

RESULTS AND DISCUSSION

Digitoxin-Poloxalene Coprecipitates.

The dissolution characteristics of

digitoxin-poloxalene test preparations are illustrated in Fig. 6 and
Table XIX.

Digitoxin present in both 10 and 1% coprecipitates dissolves

at a significantly higher rate than the pure drug.

The 1% coprecipitate

releases the drug much faster than the 10% coprecipitate.

Several fac

tors which could be contributing to this enhanced rate of dissolution
were investigated.

The factors considered were:

digitoxin-alcohol solvate,

(a) The formation of

(b) the formation of a digitoxin-poloxalene

complex having greater solubility than the pure drug, and, (c) the form
ation of an amorphous or polymorphic form of digitoxin due to coprecipi
tation of the drug with the carrier.
Digitoxin is known to form solvates with alcohol which are
stable in vacuo (78).

Drug solvates have been known to have markedly

different rates of dissolution compared to the pure drugs (99).

There

fore, the effect of treating (dissolving in alcohol and removing the
solvent in vacuo) digitoxin on the letters dissolution rate was studied.
As shown in Fig. 6, such a treatment causes digitoxin to dissolve at a
slightly faster rate than the untreated drug.

The small difference in

the dissolution rates of the pure and treated drug does not account for
the considerably faster dissolution of the drug from the coprecipitates.

75
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Figure 6.— Dissolution rates of digitoxin from poloxalene test
preparations.
Key: 0 , treated d r u g ; V , 10% physical
mixture; □ , 1% physical mixture;
10% coprecipitate;
0 , 1% coprecipitate; g , untreated drug.
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The 1% coprecipitate dissolved significantly faster than the 10%
coprecipitate.
the latter.

The former contains eleven times as much poloxalene as

Complete dissolution of the carrier present in the 1% co

precipitate yields a 0.297% solution which is about three times the CMC
value of this surfactant.

Surface active agents increase the dissolu

tion rate of drugs either bacause of lowering of interfacial tension be
tween the drug particle and the dissolution medium, which results in an
increase in the effective surface area of the drug, or due to mi cellar
solubilization.

Therefore, the effect of two poloxalene concentrations,

0.027% and 0.297%, corresponding to the 10 and 1% coprecipitates respec
tively, on the dissolution of the drug was studied.

Digitoxin was found

to dissolve at a faster rate in the presence of both the surfactant con
centrations than in plain water.
Equilibrium solubility in the above surfactant solutions (0.027%
and 0.297%), at 37®, was determined.

No difference was observed between

the solubility of digitoxin in water (0.62 mg/100 ml) and in the surfac
tant solutions.

When the solubility of a drug is increased by a surfac

tant, an interaction of the two entities is suspected.

The results of

equilibrium solubility studies indicate lack of drug-carrier interaction.
The slightly faster dissolution of the drug in the more concentrated
poloxalene solution (Fig. 6) might be due to better wetting of the drug.
Since the above mentioned facts indicate that the enhanced dis
solution of digitoxin from the coprecipitates cannot be fully accounted
for as due to solvate formation, surface tension-lowering by the carrier,
or due to drug-carrier complexation, other factors must be considered.
The enhanced dissolution of digitoxin from the coprecipitates and the
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difference between the rate of solution of the 10 and 1% coprecipitates
seems to be a particle size-effect (1053.

During the preparation of the

coprecipitate, initially both the drug and the carrier are in solution.
As the solvent gets evaporated, a supersaturated solution results.

This

is apparent because all the material still remains in solution although
the quantity of

solvent is reduced to a much smaller volume than that

required to get

the drug and carrier to dissolve initially.

The super

saturated solution finally loses enough solvent and a rapid precipita
tion of the two

components occurs.

The short time interval for the

complete removal of the solvent causes the drug to precipitate in ex
tremely fine form.

Because the ratio of drug to carrier is much smaller

in the 1% coprecipitate, crystallization of the drug might be hindered
more and much finer crystals might result compared to the 10% system.
Preliminary In vivo absorption studies were undertaken to find
if the In vitro dissolution enhancements of digitoxin from its copreci
pitates cause a similar increase in the absorption of the drug from the
GI tract.

Drug absorption may be assessed indirectly by determining its

oral toxicity (107).

This method is based on the fact that the toxicity

of an orally administered drug is directly proportional to the logarithm
of the amount of drug in the body which in turn is directly proportional
to its rate of absorption from the GI tract.

Oral drug absorption was

assessed by determining the number of deaths in mice given the same dose
of digitoxin as pure drug, as 10% w/w drug-carrier physical mixture and
as 10% w/w drug-carrier coprecipitate.
studies are summarized in Table XX.

The results of the toxicity

The administration of digitoxin as
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TABLE XX

Oral Toxicity of Various Digitoxin
Preparations in Mice&

Test System
Digitoxin

Number of
Animals Dead^

Percentage Mortality

6

20

Digitoxin-Poloxalene
Coprecipitate

29

97

Digitoxin-DCAC
Coprecipitate

30

100

Digitoxin-Poloxalene
Physical Mixture

11

37

Digitoxin-DCAC
Physical Mixture

9

30

Poloxalkold

0

0

DCA®

0

0

^A dose of 70 mg/kg digitoxin was administered as a suspension in
0.5% methyl cellulose. Thirty animals were used for each test
system.
bAnimals observed for 7 days post administration.
^A 700 mg/kg dose was administered containing 10% w/w digitoxin.
^2.7 g/kg dose.
®630 mg/kg dose.
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a coprecipitate with poloxalene caused a significant (p <0.001) increase
in its oral toxicity.

The administration of a physical mixture did not

result in a significant change in oral toxicity.

Administration of up

to 2.7 g/kg poloxalene alone did not result in any deaths.
agreement with the reported toxicity for poloxalene (86).

This is in
Most of the

mice given toxic doses of the coprecipitated drug died at a much earlier
time than those dosed with the pure drug or the physical mixture.

Wliile

62% of the deaths resulting from the coprecipitate occurred between 12
and 36 hours post administration, only 33% of the deaths due to the pure
drug occurred in 72 hours.

The observed increase in the toxicity of

digitoxin-poloxalene coprecipitate is attributed to an increase in the
rate and possibly the extent of oral absorption.

The markedly higher

toxicity of the coprecipitated drug as compared to the pure drug does
not necessarily imply that digitoxin, when administered alone, is less
available to the body than when administered in the form of the copreci
pitate.

It suggests, however, that the peak level of digitoxin in the

body after oral administration of the coprecipitate is far higher than
that achieved following an equal dose of pure drug.

Digitoxin is a hy

drophobic drug which is passively absorbed and whose absorption is ratelimited by the rate at which it goes into solution in the GI fluids.

In

this type of absorption pattern, any increase in the rate of solution of
the drug in the GI fluids would produce a corresponding increase in its
absorption rate.

Since dissolution must precede absorption, a faster

dissolving form of the drug should be absorbed at a more rapid rate and
possibly accumulate in the body to a greater extent than an equal dose
of a slowly dissolving form of the same drug.
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Digitoxin-DCA Coprecipitates.

Figure 7 shows the dissolution of digi

toxin form the DCA test systems.

The coprecipitates dissolve much faster

than the pure drug and the 1% coprecipitate goes into solution more
rapidly than the 10% preparation, at least in the initial stages.

This

difference could not be due to the bulk effect of the carrier because
the dissolution of digitoxin from the 10 and 1% physical mixtures pro
ceeded at almost equal rates.

The studies with physical mixtures indi

cate that the mere presence of the carrier in amounts equivalent to
those present in the coprecipitates is not responsible for the enhanced
dissolution of digitoxin from the coprecipitates.

Solvate formation

has already been shown not to effect the dissolution of digitoxin sig
nificantly.

That there is no interaction between digitoxin and DCA was

shown by the solubility studies (Table XXI),
Therefore,

it is proposed that coprecipitating the drug with the

carrier caused the

former to crystallize in extremely fine form or to be

present in an amorphous form and that this particle size difference is
the reason for the faster dissolution and increased solubility of the
coprecipitated drug.
Both the DCA and poloxalene coprecipitates achieve supersatura
tion,but there is

no indication of drug precipitation and the decline

towards the equilibrium value, as was the case with digitoxin-PVP co
precipitate reported by Stupak and Bates (107).
A very distinct difference exists in the pattern of dissolution
of digitoxin-poloxalene (Fig. 6) and digitoxin-DCA coprecipitates (Fig. 7)
The drug from the poloxalene coprecipitates goes into solution very
rapidly during the first 30 minutes.

After this period there is almost
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Figure 7.— Dissolution rates of digitoxin from deoxycholic acid test
preparations.
Key: ■ , untreated drug; # , treated drug;
A , 1% and 10% physical mixtures; ^ , 10% coprecipitate;
0 , 1% coprecipitate.
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TABLE XXI

Effect of Poloxalene and Deoxycholic Acid on
Solubility of Digitoxin in Water at 37°

Solubility (mg/100 ml)

W a t e r ..........................................

0.62

Poloxalene in concentration
equivalent to 10% coprecipitate ............

0.61

Poloxalene in concentration
equivalent to 1% coprecipitate

0.60

............

Deoxycholic acid in concentration
equivalent to 10% coprecipitate ..............

0.61

Deoxycholic acid in concentration
equivalent to 1% coprecipitate
...............

0.64
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no change in the amount of the drug in solution.

In contrast, the DCA

coprecipitates release digitoxin over a greater length of time.

This

difference in the release pattern of the drug could be due to the dif
ferences in the solubility of the two carriers in water.

Since polox

alene is highly soluble, it dissolves rapidly and all the drug dispersed
in it comes in contact with the dissolution medium.

On the other hand,

DCA, because of its low solubility, does not let all the dispersed drug
come in contact with the dissolution medium immediately.
The shape of the dissolution curves of the DCA coprecipitates
(Fig. 7) suggests one or the other of the following.

The initial steeply

rising portion may represent the dissolution of the drug present on the
surface of the carrier or it may represent the dissolution of a high
energy (amorphous) form of the drug.

Once this surface-dispersed or

high-energy form dissolves, the dissolution is rate-limited by the leach
ing out of the drug present in the interior of the carrier or by the
erosion of the drug crystals.
The oral toxicity studies of digitoxin-DCA test preparations are
summarized in Table XX.

The administration of digitoxin as a coprecipi

tate with deoxycholic acid caused a significant (p <0.001) increase in
oral toxicity.

Once again the mice which received the coprecipitate

died much sooner than those dying from the physical mixture.

Of thirty

mice which received plain DCA in amounts equivalent to that present in
the coprecipitate, none died.

The inherent toxicity of DCA is therefore

not a contributing factor to the enhanced toxicity of the coprecipitated
drug which seems to be due to an increase in the rate at which the drug
is absorbed from the coprecipitate.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

88
In Vitro~ln Vivo Correlation.

A linear relationship was found to exist

between the amount of digitoxin in solution (from the poloxalene and DCA
preparations) at all sampling times and the number of deaths in seven
days.

As an example, the correlation between the amount of digitoxin.

dissolved at the 60 minute period and toxicity is plotted in Figure 8.
The line of best fit was drawn by the method of least squares and the
corresponding equation and the r value is given below:
y = 4.6357 x

+

3.9735

r = 0.9976

Digoxin-Poloxalene Coprecipitates.

The dissolution characteristics of

digoxin from poloxalene test systems are illustrated in Figure 9 and
Table XXII.

The coprecipitates dissolve significantly faster than the

pure drug and the 1% coprecipitate dissolves faster than the 10% copre
cipitate.

It was found that precipitating digoxin from ethanol did not

significantly alter the dissolution of the drug.

Though the physical

mixtures show a significant enhancement of drug dissolution, there was
no difference between the 10 and 1% mixtures.

Equilibrium solubility

studies (Table XXIII) indicate that poloxalene increases drug solubility
to a small extent.

It is evident, however, that though the surface

tension-lowering and solubilizing effect of poloxalene do contribute to
the enhanced dissolution of the coprecipitated drug, these effects do
not fully account for the differences in dissolution of the pure and
coprecipitated drug.

It is probable, therefore, that coprecipitation

causes the drug to be present as fine particles and in a finer form in
the 1% coprecipitate, resulting in faster drug dissolution.
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30

24

Uh
O

18

j-i

<u

12

mg digitoxin in solution at 60 min.
Figure

8 . --Correlation between the amount of digitoxin in solution at
60 minutes and the number of mice dead in 7 days.
Key;
0 , pure drug; A , physical mixture with CCA; O , physical
mixture with poloxalkol; A , DCA coprecipitate; ^ , polox
alene coprecipitate.
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Figure 9.— Dissolution rates of digoxin from poloxalene test
preparations.
Key: # , treated drug; □ , untreated drug;
A > 1% and 10% physical muxtures; © , 10% coprecipitated;
0 , 1% coprecipitated.
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TABLE XXII

■o
CD

Dissolution Rate Studies of Digoxin
Test Preparations in Water at 37"

(
(/
/)
)
o'
=5

2,

Concentration of Digoxin^ (yg/ml) in Solution from
Test Systems

CD

8
S'
3
i
=3
CD

C

I

II

III

30

0.83

2.68

19.30

60

1.37

4.08

90

1.88

120

V

VI

VII

VIII

7.02

29.55

7.02

3.84

6.33

13.14

6.98

22.40

9.75

29.87

9.75

5.15

8.24

14.91

8.43

5.10

23.66

11.25

30.00

11.25

6.02

9.21

16.11

9.20

2.37

6.02

24.41

12.25

30.00

12.25

6.48

9.90

16.96

10.05

150

2.84

6.80

24.94

12.91

30.00

12.91

7.04

10.54

17.44

10.35

180

3.27

7.53

25.58

13.29

30.00

13.29

7.26

10.70

18.04

10.80

Time (minutes)

IV

IX

X

=T
CD

CD

■o

I
C

a
o
3
■o
o

&
o

c

I
II

(
)
(/g
o'
3

III
IV

Treated drug
Untreated drug
10% coprecipitate with poloxalene

VI
VII
VIII

10% coprecipitate with deoxycholic acid
10% physical mixture with deoxycholic
acid

10% physical mixture with poloxalene
IX

V

1% physical mixture with poloxalene

1% coprecipitate with deoxycholic acid

1% coprecipitate with poloxalene
X

^Mean of two experiments

1% physical mixture with deoxycholic
acid
to
K)
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TABLE XXIII

Effect of Poloxalene and Deoxycholic Acid
on Solubility of Digoxin in Water at 37°

Solubility (mg/100 ml)

W a t e r ..........................................

3.47

Poloxalene in concentration
equivalent to 10% coprecipitate ............

4.77

Poloxalene in concentration
equivalent to 1% coprecipitate

............

5.38

Deoxycholic acid in concentration
equivalent to 10% coprecipitate ............

4.62

Deoxycholic acid in concentration
equivalent to 1% coprecipitate
............

4.25
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Table XXIV summarizes the results of the oral toxicity studies.
Digoxin-poloxalene coprecipitate was no more toxic to mice than the plain
drug.

This finding indicates at least in the case of oral toxicity

studies, that dissolution and oral absorption do not always correlate.
It is probable that the interaction between the drug and the carrier has
a negative effect on the oral absorption of the drug.

Digoxin-DCA Coprecipitates.

The dissolution of digoxin from DCA copre

cipitates (Fig. 10) proceeds at a faster rate compared to the dissolution
of the pure drug.
drug.

The physical mixtures also dissolve faster than the

The dissolution of the drug from both physical mixtures proceeds

at a rate that is higher than its dissoluiton from the 10% coprecipitate.
Equilibrium solubility studies (Table XXIII) indicate a possible inter
action between digoxin and DCA.

It seems that the presence of an extra

hydroxyl group in digoxin (compared to digitoxin) results in molecular
interaction between the drug and both the carriers.

The oral toxicity

in mice of the 10% digoxin-DCA coprecipitate (Table XXIV) did not signi
ficantly increase beyond that of plain DCA (in the amount present in the
coprecipitate).

It is probable that the toxicity of the plain carrier

is masking any increase in oral absorption, and hence toxicity, of the
coprecipitate.

It is also possible that the interaction between the

drug and the carrier, which is indicated by the solubility studies, has
a negative effect on the oral absorption of the drug.

Effect of Aging on the Dissolution of Coprecipitated Drugs.

It was found

by Chiou and Niazi (19) that an aged sample of sulfathiazole-urea solid
dispersion dissolved at a slower rate than the freshly prepared sample.
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TABLE XXIV

Oral Toxicity of Various Digoxin
Preparations in Mice^

Test System

Number of
Animals Dead^

Percentage Mortality

Digoxin

1

3

Di goxin-Poloxalene
Coprecipitate

0

0

30

100

Digoxin-DC A<^
Physical Mixture

26

87

DCA^

27

90

Digoxin-DCA^
Coprecipitate
Digoxin-Poloxalene
Physical Mixture

^Dose of 300 mg/kg digoxin was administered as a suspension in
0.5% methyl cellulose. Thirty animals were used for each test
system.
^Animals observed for 7 days post administration.
‘'A 3 g/kg dose was administered containing 10% w/w digoxin.
^2.7 g/kg dose.
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Figure 10.— Dissolution rates of digoxin from deoxycholic acid test
preparations.
Key: 0 , treated drug;
, 10% copreci
pitate; A , 1% and 10% physical mixtures; 0 , 1%
coprecipitate; □ , untreated drug.
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The effect of aging on the dissolution of some digitoxin preparations is
shown in Figure 11 and Table XXV and that of some digoxin preparations
is shown in Figure 12 and Table XXVI.

X-Ray Diffraction Studies.

The x-ray diffraction technique was used to

find if the drugs and the carriers had undergone crystalline modifica
tions due to treatment by the solvent.

The diffraction spectra of

treated digitoxin and treated DCA were found to be different from those
of the untreated samples and are presented in Figures 13 and 14 respec
tively.

No differences in the diffraction patterns of digoxin and polox

alene were noted due to treatment with ethanol.
The x-ray diffraction technique has been used by some authors
(18, 20, 21) to study the nature of solid dispersions obtained.

In this

study, the coprecipitates gave the diffraction patterns of the carriers
only, as did the physical mixtures.

Though the x-ray studies do not

rule out the formation of solid solutions or the presence of the drug in
an amorphous form in the coprecipitates, the x-rays do not confirm any
of these possibilities either, because simple dilution with the carrier
masked the diffraction peaks of the drug.

SUMMARY

The influence of two medicinal surfactants, poloxalene and dioctylsodium sulfosuccinate on the dissolution behavior of sulfisoxazole
and sulfadiazine in pH 6 buffer was investigated.

A dramatic increase

in the dissolution rate of both the drugs was observed in the presence
of all concentrations of the surfactants.

The effect of the surfactants
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Figure 11.--Effect of aging on the dissolution rates of digitoxin
coprecipitates.
Key: A , 10% coprecipitate with
poloxalene kept at room temperature for 152 days;
freshly made 10% coprecipitate with poloxalene;
Q , 10% coprecipitate with deoxycholic acid kept at
room temperature for 146 d a y s ; Q , freshly made 10<
'%
coprecipitate with deoxycholic acid.
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TABLE XXV

Effect of Aging on the Dissolution of
Digitoxin Test Preparations

Concentration of Digitoxin (yg/ml)
in Solution from
Test Systems

III

IV

7.26

7.32

4.34

10.95

7.70

10.99

8.66

90

11.18

7.78

13.98

11.73

120

11. 23

7.85

16.13

13.76

150

11.53

7.93

17.41

15.70

180

11.45

8.01

19. 81

16.84

(minutes)

I
II
Ill
IV

I

II

30

10.44

60

Freshly made 10% coprecip itate with poloxalene
Test System I kept at room temperature for 152 days.
Freshly made 10% coprecipitate with deoxycholic acid.
Test System III kept at room temperature for 146 days.
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Figure 12.--Effect of aging on the dissolution rates of digoxin co
precipitates.
Key: Q
, 1% coprecipitate with deoxy
cholic acid kept at room temperature for 73 days;
0 , freshly made 1% coprecipitate with deoxycholic
acid; C) » 1% coprecipitate with poloxalene kept at room
temperature for 79 days; (%) , freshly made 1% coprecipi
tate with poloxalene.
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TABLE XXVI

Effect of Aging on the Dissolution of
Digoxin Test Preparations

Concentration of Digoxin (yg/ml)
in Solution from
Test Systems

1

11

111

IV

30

29.55

22.56

13.14

1.16

60

29.87

22.79

14.91

2.02

90

30.00

23.01

16.11

2.70

120

30.00

23.24

16.96

3.30

150

30.00

23.46

17.44

3.75

180

30.00

23.69

18.04

4. 08

(minutes)

I
II
Ill
IV

Freshly made 1% coprecipitate with poloxalene.
Test System 1 kept at room temperature for 79 days.
Freshly made 1% coprecipitate with deoxycholic acid.
Test System 111 kept at room temperature for 73 days.
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Figure 13.--X-ray diffraction spectra of treated (top) and untreated
(bottom) digitoxin.
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Figure 14.--X-ray diffraction spectra of untreated (top) and treated
(bottom) deoxycholic acid.
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on the absorption of the two sulfonamides from rat intestinal loops was
also studied.
was noted.

A significant but less dramatic increase in absorption

Dissolution rate and absorption could be correlated only

qualitatively.

The two surfactants had no effect on the amount of sul

fisoxazole excreted by the rat in 24 hours.
Solid dispersions of the cardiac glycosides digitoxin and digoxin
in two inert carriers, poloxalene and deoxycholic acid were prepared by
the solvent method in a 1:9 and 1:99 (w/w) ratio.

A significant improve

ment in dissolution rates was observed with all solid dispersions with
the exception of the 1:9 digoxin-deoxycholic acid system.

In all cases,

the 1:99 solid dispersions dissolved at a faster rate than the 1:9 solid
dispersions.

Biological work in mice indicated that the 1:9 digitoxin

poloxalene and digitoxin-deoxycholic acid systems to be significantly
potent than either the pure drug or physical mixtures.

The difference

in potency of the 1:9 digoxin-poloxalene solid dispersion was not signi
ficantly different from the control, although the dissolution of the
former was four to six times more rapid in in vitro experiments.

Results

suggest that no generalizations can be made about the efficacy of solid
dispersions and that dissolution rate data when used by itself, without
complimenting biological work might be misleading.

The x-ray diffraction

technique did not conclusively prove the nature of the drug in the copre
cipitates.
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